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PROPHETIC PATENTS
Janet Freilich*
In most contexts, making up data is forbidden - considered fraudulent, even
immoral. Not so in patents. Patents often contain experimental data, and it is
perfectly acceptable for these experiments to be entirely fictional. These so-called
“prophetic examples” are not only explicitly permitted by both the Patent Office
and federal courts, but are considered equivalent to factual data in patent doctrine.
Though prophetic examples are thought to be common, there are no in-depth
studies of the practice, nor any explanation for why fictional data are allowed in
patents.
Here, I provide the first historical, theoretical, and empirical analysis of
prophetic examples. I collect and analyze a novel dataset of over 2 million U.S.
patents and applications from the biology and chemistry industries. I find that at
least 17% of experiments in this population are fictional. Through both empirical
and theoretical analyses, I weigh the potential costs and benefits of prophetic
examples and find that the costs prevail. Prophetic examples could be beneficial if
they help patentees; but I find little evidence that they do so, even in the specific
situations in which they should be the most useful. Instead, prophetic examples
likely hinder innovation because they prevent others from conducting their own
experiments – even after the patent has expired and even if the prophetic example
is incorrect. Prophetic examples also hopelessly confuse scientists – a shocking
99% of scientific articles incorrectly cite prophetic examples as if they contained
factual information – which means that made-up results from patents contaminate
the scientific literature.
Given these harms, I argue for a shift from prophesies to more clearly
delimited hypotheses – roadmaps for future research, but nothing more –
preserving what value there is in speculation while mitigating the clear harms of
the practice. Beyond these concrete policy recommendations, my findings also
have rich implications for theoretical debates about the physicality of invention,
when and to whom patents should be granted, how patents transmit information,
and, ultimately, how best to incentivize innovation.
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INTRODUCTION
In May of 2005, a team of scientists made headlines after the
prestigious journal Science published a report that they had cloned human
embryos.1 Only a few months later, the team was making headlines for a
different reason: the data in the paper had been faked; Science retracted the
paper and the team’s leader, Dr. Hwang Woo-Suk, was fired and spent two
years in prison for violating bioethics rules.2 Almost ten years after the
retraction, Dr. Hwang received a U.S. patent on his discredited technique.3
Other scientists were “shocked” by the news that Dr. Hwang obtained a patent
for falsified data.4 The New York Times quoted Dr. Jeanne Loring, a stem cell
scientist at Scripps Research Institute, saying that her first reaction was, “You
can’t patent something that doesn’t exist.”5
Dr. Loring’s reaction is common, sensible, and intuitive—but wrong.
The Patent and Trademark Office (PTO) and the courts explicitly permit made
up experiments and fictional data in patents.6 Far from fraudulent, fictional
data is instead treated as equivalent to factual data.7 To illustrate, the fictional
experiment below was published in a recently granted patent:
A 67-year old male has pancreatic cancer...He is provided with A.
paucinervis pomel extract [the patented invention] for three years.
The patient is examined later and…[h]is tumor is reduced in mass...8
The supposed ability of the patented compound to cure cancer borders on
miraculous – yet it is also highly improbable, as real experiments have found
the compound to be extremely toxic.9
There is little scholarship on these fictional experiments – commonly
called “prophetic examples.” The articles that have mentioned prophetic
examples do so only in passing, with no more than a few sentences dedicated
1

Gina Kolata, Koreans Report Ease in Cloning for Stem Cells, N.Y. TIMES (May 20,
2005).
2
Andrew Pollack, Disgraced Scientist Granted U.S. Patent for Work Found to be
Fraudulent, N.Y. TIMES (Feb. 14, 2014).
3
Id. The patent in question is U.S. Patent No. 8,647,872 (issued Feb. 11, 2014).
4
Pollack, supra note 2 (“‘Shocked, that’s all I can say,’ said Shoukhrat Mitalipov, a
professor at Oregon Health and Science University who appears to have actually accomplished
what Dr. Hwang claims to have done. ‘I thought somebody was kidding...’”).
5
Id.
6
U.S. PATENT & TRADEMARK OFFICE, MANUAL OF PATENT EXAMINING PROCEDURE
[hereinafter “MPEP”] § 608 (9th ed. 2015); Atlas Powder Co. v. EI Du Pont De Nemours, 750
F.2d 1569, 1577 (Fed. Cir. 1984).
7
DONALD CHISUM, CHISUM ON PATENTS § 2212 (2015).
8
U.S. Patent No. 8,003,137, Example 15 (issued Aug. 23, 2011).
9
Frederic D. Debelle, Jean-Louis Vanherweghem, & Joelle L. Nortier, Aristolochic Acid
Nephropathy: A Worldwide Problem, 74 KIDNEY INT’L 158, 158 (2008). These experiments
were conducted before the patent issued, so they did not infringe on the patent.

to the issue.10 These articles are almost uniformly critical of prophetic
examples – hinting at potential problems surrounding the practice.11 Despite
the lack of scholarly attention, prophetic examples are common.12 It is possible
that the PTO has been granting hundreds of thousands of patents based on
fake, implausible, and unreplicable experiments – and we know nothing about
it.
In this Article, I set out to understand the history, prevalence, and impact of
prophetic examples. I collected a unique data set consisting of all prophetic and
non-prophetic examples from US patents and applications published between
1976 and 2017.13 To identify prophetic examples, I exploited a PTO rule that
requires prophetic examples to be written in the present or future tense, while
non-prophetic examples are written in the past tense.14 I focused on chemistry
and biology patents, as those are the only industries that commonly include
experimental data (real or otherwise) in patents.15 I analyzed 2,214,551 patents
10

Andrew Baluch, Relating the Two Experimental Uses in Patent Law, 87 B.U. L. REV.
213, 241 (2007) (mentioning that prophetic examples may lead to “[a]n inventor’s overreach”);
Robin Feldman, Plain Language Patents, 17 TEX. INTELL. PROP. L.J. 289, 292 (2009)
(criticizing the code for distinguishing prophetic examples); Timothy Holbrook, Possession in
Patent Law, 59 SMU L. REV. 123, 158 (2006) (explaining that prophetic examples may chill
downstream research); Timothy Holbrook, Equivalency and Patent Law’s Possession
Paradox, 23 HARV. J.L. & TECH. 1, 9 (2009) (suggesting that prophetic examples may increase
incentives to innovate); Dmitry Karshtedt, Limits on Hard-to-Reproduce Inventions, 3
HASTINGS SCI. & TECH. L.J. 109, 114 (2011) (writing about the difference between scientific
norms for reporting experiments and prophetic examples, but noting that they may disclose
valuable inventions that would not otherwise come to light); Mark Lemley, Ready for
Patenting, 96 B.U. L. REV. 1171, 1178 (2016) (suggesting that prophetic examples
“disadvantage inventors who actually build and test their inventions before filing a patent
application.”); Lisa Larrimore Ouellette, Pierson, Peer Review, and Patent Law, 69 VAND. L.
REV. 1825, 1827 (worrying that prophetic examples result in the “award of patents earlier than
is socially optimal”); Lisa Larrimore Ouellette, Who Reads Patents?, 35 NATURE
BIOTECHNOLOGY 421, 422 (2017) (noting that scientists who read patents may not be aware
that prophetic examples are not real experiments); Kristen Osenga, Cooperative Patent
Prosecution, 85 ST. JOHN’S L. REV. 115, 158 (2011) (discussing the difference between
prophetic examples and scientific writing); Sean Seymore, Patenting Around Failure, 166 U.
PENN. L. REV. (forthcoming 2018); Sean Seymore, The Teaching Function of Patents, 85
NOTRE DAME L. REV. 621, 632 (2010); Sean Seymore Heightened Enablement in the
Unpredictable Arts, 56 UCLA L. REV. 127, 144 (2009) (arguing in each article that the
experiments described in prophetic examples are probably not correct.).
11
Id.
12
Smith Kline & French Laboratories v. Teva Pharmaceuticals USA, Inc., 2006 WL
6331923 (D.Del. 2012), Expert Report of Egon E. Berg (Sept. 22, 2006) (“Based on my
experience as a patent attorney and patent examiner…prophetic examples are also common in
patents”).
13
Part III.A, infra.
14
MPEP § 608.
15
Part III.B, infra. Note that the problem of fictional experiments is certainly present in
other industries. See HAROLD FULLMER, PATENT PROSECUTION 277 (2017). Further, the theory
and policy discussed herein also applies across industries. The empirical study focuses on
chemistry and biology because the methodology is best suited to those industries. However,
the implications of this Article are not so limited.
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and applications in those industries, a population that contains 12,300,156
examples.16
I confirm that prophetic examples are indeed common: in chemistry and
biology patents issued between 1976 and 2017, at least 17% of examples are
prophetic, and, of patents with examples, at least 24% contain some prophetic
experiments.17 This means that prophetic examples are widespread enough to
seriously impact patent law – and that we need to know more about them.
At first glance, the practice of allowing prophetic examples in patents
seems baffling – why would the PTO allow fictional data? The PTO has never
explicitly stated its reasons, but it is possible to construct a strong theoretical
case for prophetic examples and then test it empirically, which I do here.
The theoretical case for prophetic examples rests on benefit to patentees.
The Patent Act requires inventors to describe how to make and use their
invention.18 Inventors often do this by writing experimental protocols and
results in the patent.19 For example, a patent on a diabetes medication might
include an experiment showing how to synthesize the molecule and another
showing that the molecule can be given to humans to reduce the need for
insulin injections.20 The broader the patent, the more experiments are
required.21 A patent covering one molecule might only need to include one
synthesis protocol, whereas a patent covering a family of one hundred
molecules might need to include many more experiments.22 It is always faster
and cheaper to make up data than to conduct real experiments, so if the
experiments disclosed in the patent can be fictional, inventors will be able to
file broader patents more easily.23 This should be particularly useful for small
companies, who have small budgets and cannot afford extensive real
experimentation.24 For companies of all sizes, broader patents provide a greater
reward to the inventor, which might incentivize more innovation.25
I test this hypothesis empirically and find there is surprisingly little
evidence that prophetic examples actually help patentees. Patents with more
16

Because some applications become granted patents, not all of these prophetic examples
are unique. See Table 1, infra, for more information.
17
Table 1 and accompanying text, infra.
18
35 U.S.C. § 112.
19
In re Wands, 858 F.2d 731, 737 (Fed. Cir. 1988).
20
U.S. Patent No. 6,916,848 col. 13, ll. 23-45, col. 67, ll. 30-67 (issued July 12, 2005).
21
See, e.g., ALZA Corp. v. Andrx Pharmaceuticals, LLC, 603 F.3d 935, 942 (Fed. Cir.
2010).
22
See, HAROLD C. WEGNER, FIRST TO FILE PATENT DRAFTING § 8:5 (2016).
23
Part II.A.1, infra.
24
Irwin Aisenberg, The Patent and Present of Working Examples, 23 IDEA 25, 30 (1982).
25
E.g., Bonito Boats, Inc. v. Thunder Craft Boats, Inc., 489 US 141, 146 (1989)
(explaining that the purpose of patents is to incentivize innovation, and that this is done, in
part, by giving inventors the exclusive right to make and use their invention).

prophetic examples are narrower than patents with fewer prophetic examples –
despite the prediction that prophetic examples help patentees get broader
patents.26 Second, there is no evidence that patents with more prophetic
examples are filed earlier than those with fewer prophetic examples – again,
contrary to prediction.27 Finally, although small companies should benefit
disproportionately from the ability to use prophetic examples, they do not. I
find that small companies are significantly less likely to use prophetic
examples as compared to their larger counterparts.28 In sum, the case for
prophetic examples does not fit with the empirical evidence.
Evidence for the benefits of prophetic examples is weak; but evidence for
their harms is much stronger. Patents with prophetic examples are frequently
abandoned, which suggests that the inventor is not commercializing their
invention.29 The problem is that, because of the patent, neither is anybody else.
While in force, the patent prevents others from working in that area. 30 Even
after the patent has been abandoned and no longer has legal force, a chilling
effect remains. Because patents are granted only if an invention has not been
previously disclosed, it is difficult for any subsequent inventor to get a patent
in an area previously described by a prophetic example.31 This is true even if
the prophetic example is incorrect and the subsequent inventor was the first to
actually make a functioning prototype.32 Essentially, instead of incentivizing
innovation, prophetic examples may create an innovation dead zone.
Prophetic examples also lead to a second type of harm: they mislead
scientists. In their patent, inventors must disclose a detailed description of their
invention that can be used by other scientists to build further upon the
technology.33 This disclosure function of patents has long been recognized as a
crucial element of innovation – allowing downstream innovators to see further
by metaphorically standing on the shoulders of giants.34 However, the
disclosure function breaks down if scientists are misled by the disclosed
information.
I analyzed how prophetic examples were cited in scientific publications
26

Part III.D.1.b, infra.
Part III.D.1.c, infra.
28
Part III.D.1.d, infra.
29
Part III.D.1.a, infra.
30
35 U.S.C. § 271.
31
35 U.S.C. § 102-103.
32
To anticipate a subsequent patent, the prior prophetic example must be enabled. MPEP
§ 2121.01. However, this is not a requirement for obviousness. Id. Further, prophetic examples
in granted patents are presumed to be enabled, so proving otherwise involves a legal battle and
is sufficient to dissuade others from working in an area. Id.
33
35 U.S.C. § 112.
34
E.g., Graham v. John Deere, 383 US 1, 6 (1966) (“…things which add to the sum of
useful knowledge are inherent requisites in a patent system which by constitutional command
must ‘promote the Progress of…useful Arts.’”).
27

Freilich

7

and found that ninety-nine percent of citations to prophetic examples
incorrectly cited the example as if it represented work that had actually been
done.35 This would not necessarily be a problem if the prophetic examples
were good predictions, but, as I demonstrate in this Article, many prophetic
examples are probably wrong.36 False information is infiltrating the scientific
community by way of prophetic examples.
My empirical findings have implications for several core debates in patent
theory, including the disclosure function of patents, theories about constructive
reduction to practice, and the optimal timing of patent filing. For disclosure,
the misinformation spread by prophetic examples adds strength to widespread
accusations that disclosure functions poorly and furthers a line of the literature
emphasizing the gap between scientific writing and “patentese.”37 For
constructive reduction to practice – a doctrine that allows inventors to obtain a
patent without having physically created the invention – scholars argue that it
disincentivizes physical reduction to practice.38 However, my evidence
suggests that, surprisingly, there may be more advantages to physical invention
than previously realized.39 For the optimal timing of patent filing, I show that
while proponents of early filing might be expected to favor mechanisms that
contribute to earlier filing, some such mechanisms – such as prophetic
examples – do not fit with the traditional justifications for early filing.40
All of this strongly argues for reform. Banning fictional experiments in
patents is an attractive solution, given the findings herein, but likely too drastic
an institutional change (for now). Instead, I argue that we should not think
about fictional experiments as prophecies – a name that carries of ring of
accuracy and infallibility – but rather as hypotheses – testable predictions that
may or may not turn out to be correct.41 The shift from prophecies to
hypotheses has several practical implications. First, it would reverse the
current legal presumption that prophetic examples are enabled (i.e. that they
work as written), since, as I show empirically, there is simply no reason to
assume accuracy. Second, we should give inventors a grace period after filing
to test their hypotheses and update prophetic examples with real results.
Finally, we should require prophetic examples to be clearly labeled and to
include some explanation about why the inventor expects the experiment to
work. These changes all reflect that the predicted results are possibilities, not
inevitabilities, and the shift can preserve what value such speculation has,
while mitigating the clear harms that now prevail.

35

Part III.D.2.b, infra.
Part IV.B.1, infra
37
Part III.D.2.b, infra
38
Part IV.B.2, infra.
39
Part IV.A.2.c, infra
40
Part IV.A.2.b, infra.
41
Part IV.C, infra.
36

The Article proceeds as follows. Part I provides background on prophetic
examples, introducing the concept and related doctrine, as well as sketching
their historical development. Part II makes the case for prophetic examples,
and discusses costs and benefits. Part III, the heart of the Article, provides a
novel empirical study of prophetic examples, explaining the study’s design and
methodology, and then providing data. Part IV then explains the study’s
results, examines the theoretical implications of the study for patent theory,
and concludes with a proposal for policy reform.
I. PROPHETIC EXAMPLES
Prophetic examples are experiments that report protocols that were not
actually conducted and describe results that are made up, or prophesized.42
There is little literature on prophetic examples,43 so this Section provides an indepth exploration of the practice of prophesy in patents. Section I(a) is an
introduction to prophetic examples and summarizes current doctrine. Section
I(b) traces the history of prophetic examples, exploring why they were
originally used and explanations for their existence.
A. Introduction to Prophetic Examples
The Patent Act requires that every patent contain a written description of
the invention as well as information on how to make and use it.44 These
disclosure requirements ensure that the inventors obtain a monopoly
commensurate with what they have actually invented.45 Disclosure is also
intended to promote innovation by ensuring that scientists and can read and use
the information in the patent and thereby build further on the technology.46 The
requirements are a quid-pro-quo to guarantee that the public receives the
benefit of knowledge in exchange for granting an exclusive patent.47 In the
absence of patents, inventions that could be kept secret might never be taught
to the public.48
The disclosure statute has two components: enablement and written

42

MPEP § 608.
Note 10, supra.
44
35 U.S.C. § 112.
45
Dan L. Burk, Patent Silences, 69 VAND. L. REV. 1603, 1606 (2016).
46
E.g., Graham v. John Deere, 383 US 1, 6 (1966).
47
Lisa Larrimore Ouellette, Pierson, Peer Review, and Patent Law, 69 VAND. L. REV.
1825, 1827 (2016).
48
Sean O’Connor & Ted Sichelman, Patent as Promoters of Competition: The Guild
Origin of Patent Law in the Venetian Republic, 49 SAN DIEGO L. REV. 1267, 1272 (2012). In
practice, some aspects of patented inventions are still kept secret. See W. Nicholson Price II,
Making do in Making Drugs: Innovation Policy and Pharmaceutical Manufacturing, 55 B.C.
L. REV. 491 (2014); W. Nicholson Price II & Arti K. Rai, Are Trade Secrets Delaying
Biosimilars, 10 SCIENCE 188, 188 (2015).
43

Freilich

9

description.49 The enablement doctrine requires that the patent include
sufficient detail to ensure that a person skilled in the field of the invention
could make and use the invention.50 The written description doctrine requires
that the patent include sufficient detail to prove that the inventor was in
possession of the invention when she filed the application.51 Possession does
not refer only to physical possession of the invention.52 The requirement can be
met if the inventor clearly describes the invention in the patent.53
These requirements can be satisfied in many ways, but it is common to
provide examples of how the invention is made or used. 54 Examples often
describe experiments, and may provide instruction on how to make a
composition or the effects of using said composition.55 They are sometimes
analogized to the “Materials and Methods” and “Results” sections of scientific
articles.56 While examples are not required,57 they are frequently included in
patents58 and the absence thereof is frowned upon by courts.59
There are two types of examples: (1) “working examples,” which report
experiments actually conducted; and (2) “prophetic examples,” which report
experiments that were not actually conducted and describe content that is made
up, or prophesized.60 The Patent Office defines prophetic examples as “an
embodiment of the invention based on predicted results rather than work
actually conducted or results actually achieved.”61 I give excerpts from
prophetic and non-prophetic examples below, to give the reader their flavor.
The following two examples come from U.S. Patent No. 6,869,610 which
claims methods of treating pain by administration of Botox.62 The patent
contains one non-prophetic example, describing experiments conducted on
rats, and several prophetic examples, describing the predicted effects of
administering Botox to humans.
49

Ariad Pharm., Inc. v. Eli Lilly and Co., 598 F. 3d 1336, 1341 (Fed. Cir. 2010).
35 U.S.C. § 112; In re Wands, 858 F.2d 731, 736 (Fed. Cir. 1988).
51
35 U.SC. § 112; Ariad, 598 F. 3d at 1341.
52
Falko-Gunter Falkner v. Inglis, 448 F.3d 1357, 1366 (Fed. Cir. 2006).
53
MPEP § 2163.02 (“An applicant shows possession of the claimed invention by
describing the claimed invention with all of its limitations using such descriptive means as
words, structures, figures, diagrams, and formulas that fully set forth the claimed invention.”).
54
MPEP § 2164.02.
55
E.g., Application of John A. Stephens, 529 F.2d 1343, 1345 (CCPA 1976).
56
PRACTICING LAW INSTITUTE, HOW TO WRITE A PATENT APPLICATION, 17-26 (2016).
57
In re Wright, 999 F.2d 1557, 1561 (Fed. Cir. 1993).
58
In re Strahilevitz, 668 F.2d 1229, 1232 (CCPA 1982).
59
See, e.g., Wyeth v. Abbott Laboratories, 2012 WL 175023, *11 (D.N.J. 2012), aff’d on
other grounds, 720 F.3d 1380, 1384 (Fed. Cir. 2013); Boston Scientific Corp. v. Johnson &
Johnson Inc., 2010 WL 183752, *13 (D.Del. 2010).
60
MPEP § 608.01(p).
61
MPEP § 2164.02. See also CHISUM, supra note 7, at § 10.05 (calling prophetic
examples “specific illustrations of the invention that have not, in fact, been carried out.”); Paul
R. Gugliuzza, Early Filing and Functional Claiming, 96 B.U.L. REV. 1223, 1226 (2016)
(calling prophetic examples “basically, educated speculations...”).
62
U.S. Patent No. 6,869,610 (issued Mar. 22, 2005).
50

Non-Prophetic
Two experiments were carried out…[using]
rats…there were 4 treatment (dose) groups:
control (saline injected) rats…and 7 U
BOTOX®/KG rats...Limb lifting/licking by
the subject animals was recorded…at both
5 days and 12 days after injection, there
was a significant dose dependent pain
alleviation in the BOTOX® treated
animals.63

Prophetic
A 46 year old woman presents with pain localized
at the deltoid region due to an arthritic condition.
The muscle is not in spasm, nor does it exhibit a
hypertonic condition. The patient is treated by a
bolus injection of…intramuscular botulinum toxin
type A. Within 1-7 days after neutrotoxin
administration the patient’s pain is substantially
alleviated. The duration of significant pain
alleviation is from about 2 to about 6 months.64

The Patent Office and the federal courts explicitly permit prophetic
examples.65 Both institutions have also confirmed that prophetic examples can
be used to satisfy the enablement and written description requirements in the
same manner as working examples could be so used. To satisfy the enablement
requirement, applicants must describe the invention sufficiently to enable
another person in the field to make and use the claimed invention.66 Prophetic
examples teach strategies for making and using the invention, and thus help
satisfy the enablement requirement.67 For the written description requirement,
applicants must disclose the invention in sufficient detail to show that they
were in possession of the invention when they filed the patent.68 Prophetic
examples help demonstrate that the patentee knew about the contours of the
invention, and thus help satisfy the written description requirement.69 Patents
must also contain a statement of utility to be valid,70 and prophetic examples
can be used to illustrate the utility of the invention.71

63

Id. at Example 1.
Id. at Example 2.
65
Atlas Powder Co. v. EI du Pont De Nemours, 750 F.2d 1569, 1577 (Fed. Cir. 1984);
MPEP § 2164.02.
66
35 U.S.C. § 112.
67
Alcon Research Ltd. v. Barr Laboratories, 745 F.3d 1180, 1189 (Fed. Cir. 2014);
Energy Absorption Systems, Inc. v. Roadway Safety Services, Inc., 1997 WL 368379, *5 (Fed.
Cir. 1997); Boston Scientific Corp. v. Johnson & Johnson Inc., 679 F.Supp.2d 539, 552
(D.Del. 2010) (“the burden is on one challenging validity to show, by clear and convincing
evidence, that the prophetic examples together with other parts of the specification are not
enabling.”); Cephalon, Inc. v. Watson Pharmaceuticals, Inc., 769 F.Supp.2d 729, 750 (D.Del.
2011).
68
Ariad Pharmaceuticals, Inc. v. Eli Lilly and Co., 598 F.3d 1336, 1343 (Fed. Cir. 2010).
69
Ariad, 598 F.3d at 1357 (confirming that prophetic examples “certainly can be sufficient
to satisfy the written description requirement”); Application of Robbins, 429 F.2d 452, 457
(CCPA 1970).
70
35 U.S.C. § 101.
71
E.g. Rebecca S. Eisenberg & Robert P. Merges, Opinion Letter as to the Patentability of
Certain Inventions Associated with the Identification of Partial Cdna Sequences, 23 AIPLA
Q.J. 1, 16 (1995) (explaining that patent examiners are sometimes skeptical of prophetic
examples illustrating utility). See also, Michael Risch, Reinventing Usefulness, 2010 BYU L.
Rev. 1195, 1202.
64
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Though prophetic examples can serve the same function as working
examples, inventors cannot pass off prophetic examples as work that has
actually been done. Prophetic examples must be written in the present tense,
while working examples are written in the past tense.72 The Federal Circuit
held that writing prophetic examples in the past tense can be inequitable
conduct,73 though district courts hearing cases on the question have produced
mixed results.74 A finding of inequitable conduct, essentially fraud, can render
the patent unenforceable.75 However, prophetic examples recited in the present
tense are unquestionably not inequitable conduct, a principle that has needed
repeating by the Federal Circuit and district courts.76
B. History of Prophetic Examples
The practice of allowing fictional information in a legal document is
unusual; it is not intuitive how such a practice might develop or why it might
be permissible. The Section below traces the development of prophetic
examples.
1. Early History
Most of the earliest U.S. patents were mechanical or electrical.77
Mechanical and electrical inventions are relatively “predictable,” meaning that
a skilled engineer reading a patent disclosing one model of an apparatus could
predict how variations of the disclosed apparatus would perform.78 This
disclosure was often a drawing of a machine (as opposed to just text), which
the skilled engineer could follow to build and use the machine.79 Over time,
this disclosure came to be considered sufficient evidence of invention – a
physical model was not needed.80 This doctrine, called “constructive reduction
72

MPEP § 608.
Hoffmann-La Roche, Inc. v. Promega Corp., 323 F.3d 1354, 1364 (Fed. Cir. 2003). See
also Purdue Pharma. L.P. v. Endo Pharmaceuticals Inc., 438 F.3d 1123, 1134 (Fed. Cir. 2006);
Novo Nordisk v. Bio-Tech Gen. Corp., 424 F.3d 1354, 1364, 1368 (Fed. Cir. 2005).
74
Compare Presidio Components Inc. v. American Technical Ceramics Corp., 2010 WL
1462757, *28 (S.D.Cal. 2010) with Apotex, Inc. v. UCB, Inc., 970 F.Supp.2d 1297, 1319
(S.D.Fla. 2013). Note that the Federal Circuit clarified the inequitable conduct standard in the
years between Presidio and Apotex. Therasense, Inc. v. Becton, Dickinson and Co., 649 F.3d
1276, 1279 (Fed. Cir. 2011).
75
American Calcar v. American Honda, 768 F.3d 1185, 1186 (Fed. Cir. 2014).
76
E.g., Energy Absorption Systems, Inc. v. Roadway Safety Services, Inc., 1997 WL
368379, at *5 (Fed. Cir. 1997); Eli Lilly and Co. v. Actavis Elizabeth LLC, 676 F.Supp.2d
352, 363 (D.N.J. 2009), rev’d on other grounds 435 Fed.Appx. 917 (Fed. Cir. 2011).
77
Sean B. Seymore, The Enablement Pendulum Swings Back, 6 NW. J. TECH. & INTELL.
PROP. 278, 282 (2008).
78
Id.
79
Drawings are still used to satisfy patent disclosure requirements. 35 U.S.C. § 113.
80
35 U.S.C. § 114 empowers the PTO to ask applicants for a model of their invention, but
“[w]ith the exception of cases involving perpetual motion, a model is not ordinarily required
by the Office…” MPEP § 608.03.
73

to practice” allowed inventors to obtain patents on anything they could
describe in sufficient detail to teach others to make, even if the inventor had
never physically made the invention.81
In the early twentieth century the field of organic chemistry burgeoned and
the number of chemistry patents skyrocketed.82 Drawings – a great aid in
teaching mechanical inventions – were less helpful for chemical patents.83
Although a drawing of a molecule shows its structure, it is not always clear
from that structure how to synthesize the molecule or what the molecule’s uses
might be. To ensure that chemistry patents had adequate disclosure of how to
make and use the invention, patent drafters turned to “examples” –
experimental protocols that supported the chemical claim in the same way that
drawings traditionally had for mechanical patents.84 Though examples were
not strictly necessary to enable a chemical invention,85 courts often rejected
chemistry patents that lacked examples86 and patent prosecutors believed that a
large number of examples would help their case.87 Examples therefore became
a standard part of chemistry patents.
Unlike the mechanical sciences, chemistry is “essentially an experimental
science and results are often uncertain, unpredictable and unexpected.”88 In
unpredictable fields, it is often not possible to predict how minor variations in
the invention will affect the results.89 The doctrine of constructive reduction to
practice assumes that predictions made without physical creation will be
accurate.90 It is therefore not clear that the doctrine should be allowed in
81

Hybritech Inc. v. Monoclonal Antibodies, Inc., 802 F.2d 1367, 1376 (Fed. Cir. 1986).
Constructive reduction to practice is supposed to be equal to actual reduction to practice. John
Duffy, Reviving the Paper Patent Doctrine, 98 CORNELL. L. REV. 1359, 1366 (2013).
Underlying the doctrine is an assumption of accuracy – that the disclosed invention will be
function and that the inventor “has” the invention. Wheeler v Clipper Mower and Reaper Co.,
6 Fisher’s Patent Cases 1, 16. If a description does not work, it is arguably not constructively
reduced to practice. See Cooper v. Goldfarb, 154 F.3d 1321, 1328 (Fed. Cir. 1998); Conover v.
Downs, 35 F.2d 59, 60 (CCPA 1929).
82
The number of patents in this field grew significantly in the early 20 th century. E.g.,
David Katz, Proposal to Improve the Patent System, 17 J. PAT. OFF. SOC’Y 777, 780-81
(1935).
83
Eugene W. Geniesse, Adequate Description, 27 J. PAT. OFF. SOC’Y 784, 784 (1945).
84
Geniesse, supra note 83, at 787 (“Illustrative examples in chemical cases serve the same
purposes as do drawings in mechanical cases.”).
85
Id. See also In re Borkowski, 422 F.2d 904, 908 (CCPA 1970) (“as we have stated in a
number of opinions, a specification need not contain a working example if the invention is
otherwise disclosed in such a manner that one skilled in the art will be able to practice it
without undue experimentation.”).
86
Harold C. Wegner, Patent Law Simplification and the Geneva Patent Convention, 14
AIPLA Q.J. 154, 194 (1986).
87
Joseph Rossman, The Rejection of Broad Chemical Claims, 14 J .PAT. OFF. SOC’Y 873,
873 (1932).
88
Schering Corp. v. Gilbert, 153 F.2d 428, 433 (1946).
89
Seymore, supra note 77, at 282; Rossman, supra note 87, at 873.
90
E.g., Cooper v. Goldfarb, 154 F.3d 1321, 1328 (Fed. Cir. 1998)
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chemical patents, even if it was standard in mechanical patents. However, there
are remarkably few records objecting to constructive reduction to practice in
chemical patents.91 Instead, it quickly became clear that constructive reduction
to practice was as acceptable for chemical patents as it was for mechanical
patents.92
…an applicant may base a [chemical] patent application wholly on
speculation…without doing any actual work…In layman’s language
this means that a patent can be secured on mere supposition without
having actually invented or discovered anything.93
The need for examples in chemical patents combined with the permissibility of
constructive reduction to practice led to use of constructive reduction to
practice in examples: prophetic examples. If a drawing of a never-built
machine could be used to enable a mechanical invention, proponents of
prophetic examples argued, then why not allow a never-conducted experiment
to enable a chemical invention?94
2. Prophetic Examples Become Patent Office Policy
For the first 50 years of prophetic examples,95 the Patent Office had no
official rules concerning the practice, but had an unofficial practice of allowing
them. In 1980, the District of Delaware sharply criticized the Patent Office,
stating that it
can conceive of no reason for the PTO to countenance such a practice.
In effect, the PTO is permitting itself to be misled by patent applicants
91

There are a small number of sources that point to the necessity of actual experiments in
chemical patents. Rossman, supra note 87, at 874.
92
Undue Breadth—Disclosure of Single Metal as Masking Material in Welding Operation
Held Insufficient Basis to Support Claim Directed Broadly to ‘Material’, 29 J. PAT. OFF.
SOC’Y 455, 458 (1947) (“Many patents are undoubtedly granted on structures proposed in
drawings but which structures have never been actually made, and seemingly the practice does
not forbid the same sort of presentation with respect to phenomena not predictable with
certainty such as is found in chemistry…”).
93
Geniesse, supra note 83, at 788.
94
Rossman, supra note 8787, at 875 (citing an unnamed Board of Patent Appeals and
Interferences case: “We know of no authority which denies protection when applicants may
not have actually produced the compounds he claims as his invention…but which he has
visualized as the reaction product of known materials. In the mechanical field protection is
given to inventions which are constructively reduced to practice…The description of a new
compound by its formula or name in terms of standard nomenclature is analogous to the
description and drawing of a machine…Applicants have complied with these rules by
[prophetically] telling how the compounds can be made and how they can be used.”).
95
The earliest mention of prophetic examples I was able to find came from a case in 1927
where the 6th Circuit noted that a patent’s reference to “certain grades of untreated cassava”
might be “perhaps merely prophetic, because the record indicates that [the inventor] had not
found any raw starch which would perform properly…” Perkins Glue Co. v. Holland Furniture
Co., 18 F.2d 387, 387 (6th Circ. 1927). Prophetic examples may have been used earlier.

during the process of granting a monopoly. Moreover, the public is
mislead by such misrepresentations.96
Shortly thereafter – and perhaps because of the criticism97 – the Patent Office
made its first official statement on prophetic examples, adding them to the
Manual of Patent Examination Procedure in 1981. The PTO originally inserted
a provision stating that
Applicants must indicate which tests and examples are only
simulated or predicted and which tests and examples have actually
been carried out to permit the examiner to examine the same
properly. Simulated or predicted tests are ‘paper’ examples and
must not be confused with actual working examples. Working
examples…must be written in the past tense…Paper examples,
however…must be written in the present or future tense…98
… Clarity as to test results is essential because patent examiners
have relatively little or no resources to test the veracity of
representations made by applicants.99
This provision was inserted with no advance notice100 or discussion.101 The
provision dismayed some attorneys, who felt it restricted patent protection.102
After 9 months, the PTO withdrew most of the provision, leaving only the
statements that prophetic examples are permitted in patent applications and
that they must be described in the present tense while working examples are

96

Grefco, Inc. v. Kewanee Industries, Inc., 499 F.Supp. 844, 868 (D.Del. 1980).
American Patent Law Association Midwinter Meeting – Committee Reports, 1983
APLA 208, 209 (1983) (“Statements by the Court in Grefco…prompted the short lived
January 1981 version of the MPEP §608.01(p) on ‘Simulated or Predicted Tests or
Examples.’”). See also, Donald G. Dau, Chemical Names as Anticipation and Support, 70 J.
PAT. & TRADEMARK OFF. SOC’Y 377, 394 (1988) (“It is rumored…that the deleted changes
had been responsive to criticism of the PTO in Grefco Co. v Kewanee Industries…”).
98
MPEP
§
608.01(p),
104
(Rev.
5,
Jan
1981),
available
at
http://www.uspto.gov/web/offices/pac/mpep/old/E4R5_600.pdf.
99
Id.
100
Donald G .Daus, Chemical Names as Anticipation and Support, 70 J. PAT. &
TRADEMARK OFF. SOC’Y 377, 394 (1988) (“The provisions had been inserted in the MPEP
without advance notice. No ‘grandfather’ exceptions had been recited.”).
101
Irwin M. Aisenberg, The Patent and Present of Working Examples, 23 IDEA 25, 25
(1982) (complaining that this “fundamental alteration in disclosure requirements should clearly
require an appropriate statutory enactment rather than an insert in the M.P.E.P.”).
102
Id. at 27 (1982) (“it is not within the examiner’s domain to limit available or to
challenge support of claim scope by differentiating between examples which reflect concluded
experiments and those which do not. It is highly questionable whether an examiner even has a
right to ask which examples are merely ‘paper’ examples….The Rules still fail to provide any
authority for distinguishing between examples which reflect an actual reduction to practice and
those which do not.”).
97
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described in the past tense.103 Specifically, the provision prohibiting results in
prophetic examples was removed, as was the exhortation for clarity and the
explanation that patent examiners cannot test the veracity of statements in
patents.104 The PTO did not clarify the reason for the change, stating only that
the original provisions “went further than was intended.”105
Though the PTO did not specify why it chose to permit prophetic
examples, the original statement in the MPEP suggests that it may have been a
question of administrative necessity. The PTO may simply not have the
capacity to check whether an invention had been physically made. The PTO
suggested as much in its original MPEP statement noting that examiners have
“little or no resources to test the veracity of representations made by
applicants.”106 Scholars have suggested that the PTO originally accepted the
doctrine of constructive reduction to practice for the same reason.107
3. Prophetic Examples in Recent Case Law
The law of prophetic examples has stayed substantially static since 1981.
The relevant provision in the MPEP has not changed.108 Case law has by and
large simply pointed to the MPEP as a source of permission for prophetic
examples. Most cases that address prophetic examples simply accept that the
prophetic example supports the invention and include no discussion of the
examples’ value or any controversies or doctrinal points. 109
103

MPEP, supra note 98, at § 608.01(a).
Id.
105
1038 OFFICIAL GAZETTE 100 (Nov. 5, 1981) (“The wording of the MPEP provisions
prior to this amendment went further than was intended. The amended sections below spell out
more clearly the Office’s position from the start.”).
106
MPEP, supra note 98, at § 608.01(a). Alternatively, the PTO’s reluctance to question
whether the application of a rule that worked for mechanical patents was appropriate for
chemical patents may be a result of the insularity of the patent bar. See John Duffy, Rethinking
Patent Law’s Uniformity Principle, 101 NW. L. REV. 1619, 1645 (2007) (exploring the
consequences of the Federal Circuit’s exclusive jurisdiction on the insularity of patent law, but
noting that even before the Federal Circuit “the patent bar was a recognized specialty and a
somewhat insular community.”).
107
Duffy, supra note 81, at 1370 (explaining that the PTO has “little or no ability to
investigate the underlying physical reality of inventions.”). Moy’s Walker on Patents puts the
matter more pointedly by noting that the doctrine is “an attempt to provide a theoretical basis
for a problematic practice of the PTO…during examination the PTO does not inquire whether
applicants have actually reduced their claimed inventions to practice. Thus, patents routinely
issue on inventions that were not constructed as of the filing date.” § 8:93 Conceptual
Inconsistencies – Constructive Reduction to Practice (4th ed. 2017).
108
MPEP § 608.01(a) (9th ed. Rev. 07.2015, Nov. 2015).
109
See, e.g., Phigenix Inc. v. Genentech Inc., 2016 WL 4172202, *1 (N.D.Cal. Aug. 8
2016). (“[the patent] describes prophetic examples that predict that this phenomenon also
occurs in breast cancer cells.”); Regeneron Pharmacueticals v. Merus, 2014 WL 6611510, at
*18 (S.D.N.Y. 2014) (“Example 3 (a prophetic example), confirms human genomic DNA.”);
Ex Parte Artemis Medical Inc., 2010 WL 4084621, *3 (BPAI 2010) (“Anderson’s Prophetic
Example 2 describes the preparation of a copolymer obtained by polymerizing lactic acid and
glycolide monomers.”); Ex Parte Ignatius Loy Britto, 2008 WL 2781982, *3 (BPAI 2008)
104

Though it is well settled that prophetic examples can be used to satisfy the
disclosure requirements, the issue still arises frequently, suggesting that
litigants remain somewhat skeptical. This skepticism is not entirely unfounded.
The Wands factors, which embody the seminal test for enablement, list the
presence or absence of “working examples” as a factor in the analysis, but omit
prophetic examples.110 Furthermore decision-makers, including the Board of
Patent Appeals and Interferences (“BPAI”) and Patent Trial and Appeal Board
(“PTAB”), will often hint that prophetic examples are not quite as good as
working examples by prefacing prophetic evidence with a word suggesting
hesitation, such as bemoaning the lack of “working or even prophetic
examples.”111
Overall, caselaw on prophetic examples remains sparse.112 An April 2017
search for cases mentioning the term “prophetic example” uncovered only 52
cases in Westlaw’s Federal Cases database and 46 and 12 cases from the Board
of Patent Appeals and Interferences and Patent Trial and Appeal Board
databases, respectively.113 Searches for “paper example” found few relevant
cases, suggesting that the dominant terminology is “prophetic” rather than
“paper.”
II. THE CASE FOR PROPHETIC EXAMPLES
There has never been any thorough examination of why we permit
prophetic examples. Allowing fictional data in patents is, at first glance, a
(“Prophetic Examples 3 and 13 describe the use of PTFE-PES blend…”); Ex Parte David I.
Gwynne et al., 2000 WL 33118608, *4 (BPAI 2000) (“The examiner points to Yelton’s
prophetic example…which describes cloning and expression of a foreign polypeptide…”).
110
In re Wands, 858 F.2d 731, 737 (Fed. Cir. 1988).
111
Enzo Biochem, Inc. v. Applera Corp., 2013 WL 3965305, *8 (D.Conn. 2013). See also,
Ariad, 598 F.3d, at 1357. See also Takeda v. Handa, 2013 WL 9853725, *72 (N.D.Cal. 2013)
(finding that the patent “does not contain any working examples…instead, all of the
examples…[are] prophetic…”); Ex Parte Robert C. Lam, 2008 WL 503540, *3 (BPAI 2005)
(“The only examples provided are two ‘prophetic’ examples”) (emphasis added); Ex Parte
Katherine W. Klinger, 2006 WL 2523659, *2 (BPAI 2003) (“The application is devoid of
working examples and/or models…However, as Appellants note…the Specification does
include prophetic examples.”) (emphasis added). Similarly, courts have found prophetic
examples based on actual experiments to be a particularly convincing flavor of prophetic
example. E.g., Warner Lambert Co. v. Teva Pharmaceuticals USA, Inc., 2007 WL 4233015,
*11 (D.N.J.) (“the ‘prophetic’ examples of the specification were based on actual experiments
that were slightly modified in the patent to reflect what the inventor believed to be optimum,
and hence, they would be helpful in enabling someone to make the invention.”).
112
Rothschild v. Cree, Inc., 711 F.Supp.2d 173, 209 (D.Mass. 2010) (“There are very few
cases dealing with prophetic examples in patents.”).
113
The Board of Patent Appeals and Interferences (BPAI) and the Patent Trial and Appeal
Board (PTAB”) are administrative bodies within the PTO that hear appeals of patent
examinations and related issues. 35 U.S.C. 6(b). The BPAI was renamed the PTAB in 2012 (at
which point the BPAI ceased to exist), and Westlaw indexes decisions from the boards in
separate databases.
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perplexing practice114 – and the scholarly literature on prophetic examples,
though brief, is overwhelmingly negative.115 Nonetheless, there is a serious
theoretical case to be made for the benefits of prophetic examples, and I make
that case in this section. In doing so, I create a series of testable hypotheses that
I evaluate empirically in Section III.
The purpose of patents is to incentivize innovation.116 Inventors are
motivated by the knowledge that they will receive patent exclusivity as a
reward.117 Roughly speaking, stronger, bigger, and more effective patent rights
increase this reward.118 The most convincing explanation for prophetic
examples is that they help patentees, thereby strengthening the exclusivity
incentive for innovation. In Part A, below, I hypothesize that prophetic
examples can lead to patents that are broader and filed earlier than would be
possible in the absence of prophetic examples.
To make the case for prophetic examples, it is not enough that they help
patentees. They must also not be harmful. In Part B, I make explicit two
additional requirements that must be satisfied to justify the use of prophetic
examples. First, prophetic examples should not impede innovation in the area
described by the patent. Second, prophetic examples should be consistent with
the underlying logic of patent law.
A. Potential Benefits
1. Earlier-Filed, Broader Patents
Patent applications with prophetic examples can be filed earlier than
applications with working examples because writing a prophetic example is
faster than conducting even the simplest of real experiments.119 Moreover, real
experiments might not work or might produce unexpected data, necessitating a
potentially time-consuming change to protocols or development of a new
procedure. Prophetic examples do not have this potential. Thus, applicants who
choose prophetic examples will be able to file a patent application earlier than
114
For example, one court complained that it “can conceive of no reason for the PTO to
countenance such a practice.” Grefco, Inc. v. Kewanee Industries, Inc., 499 F.Supp. 844, 868
(D.Del. 1980).
115
See all references cited in note 10, supra.
116
E.g., Diamond v. Chakrabarty, 447 US 303, 307 (1980).
117
See, e.g., Peter S. Menell & Suzanne Scotchmer, Intellectual Property Law, in 2
HANDBOOK OF LAW AND ECONOMICS 1473, 1476-78 (A. Mitchell Polinsky & Steven Shavell
eds., 2007).
118
E.g., Robert P. Merges and Richard R. Nelson, On the Complex Economics of Patent
Scope, 90 COLUM. L. REV. 839, 840 (1990).
119
As one guide notes: “Situations may arise when an inventor has a great idea but has no
time for lengthy experimentation or time-consuming data collection…In such instances, the
filing of a prophetic patent application may be the solution…” JOSEPH P. KENNEDY, ET AL,
HOW TO INVENT AND PROTECT YOUR INVENTION: A GUIDE TO PATENTS FOR SCIENTISTS AND
ENGINEERS, § 5.5.3 (2012).

applicants who choose to conduct experiments, a particular advantage in
competitive and fast-moving fields.120
Prophetic examples also help applicants obtain broader patents. Patents
must teach others how to make and use their inventions, and a broader patents
covering more material require more teaching. To get a patent on one
molecule, one experimental protocol is generally enough to teach how to
synthesize the molecule.121 To get a patent on many different molecules, many
synthesis protocols will be needed. Thus, patent drafters will try to include
more examples to support broader claims.122 Prophetic examples are
instrumental to this function.123 Prophetic examples also allow applicants to
seek a broad patent without conducting expensive experiments, which reduces
the cost of patents.
The following example illustrates how prophetic examples allow for
broader, cheaper, and earlier-filed patents. Para-dichlorobenzene, the molecule
historically used in scented deodorizers, was suspected to be toxic.124 To solve
this problem, a pair of inventors discovered a new molecule that could be
combined with various scents and would slowly releases those scents over time

120

Practicing Law Institute, How to Write a Patent Application, 17-36 (2016). See also
ROBIN FELDMAN, RETHINKING PATENT LAW, 160 (2012); Tom Brody, CLINICAL TRIALS, 837
(2016) (“Prophetic examples can be [used if]…the inventors did not have enough time to
complete, or even initiate, any of the relevant experiments before the patent application was
filed.”).
121
MPEP § 2164 (explaining that “A single working example in the specification for a
claimed invention is enough to preclude a rejection which states that nothing is enabled since
at least that embodiment would be enabled. However, a rejection stating that enablement is
limited to a particular scope may be appropriate.”).
122
See, e.g., Enzo Biochem. Inc. v. Calgene, Inc., 188 F.3d 1362, 1374 (Fed. Cir. 199)
(holding that the patent was not valid because “the number of working examples provided in
the specifications were ‘very narrow,’ despite the wide breadth of the claims at issue…”).
123
See, e.g., Brody, supra note 120, at 837; Troy Groetken, IP: Sufficiency of Disclosure
and the Great Divide Between U.S. and Europe, INSIDE COUNSEL (February 26, 2014),
available at http://www.insidecounsel.com/2014/02/26/ip-sufficiency-of-disclosure-and-thegreat-divide (“[M]any times, the actual examples provided do not provide the same level of
breadth as the written word descriptive sections attempting to broaden the claimed invention.
To overcome this, a number of prophetic examples are sometimes included in the
specification”); WILLIAM G. KONOLD, WHAT EVERY ENGINEER SHOULD KNOW ABOUT
PATENTS, 54 (1989); William B. Slate, The Real Security of Continuation-in-Part
Applications, 83 J. PAT. & TRADEMARK SOC’Y 551, 554 (2001); PRACTICING LAW INSTITUTE,
BIOTECHNOLOGY LAW: BIOTECHNOLOGY PATENTS AND BUSINESS STRATEGIES IN THE NEW
MILLENNIUM, 359 (2002). For example, in Synthes v. Spinal Kinetics, the Federal Circuit held
that disclosure of one species in an unpredictable field was insufficient support for a broad
genus. 734 F.3d 1332, 1334 (Fed. Cir. 2013). Following this case, practice guides
recommended that to “avoid or minimize problems such as those in…Synthes…the applicant
could have included prophetic examples…” Helene C. Carlson and Gaby L. Longsworth,
Strengthening Pending and Future Application Portfolios in Advance of Potential Attack in
AIA Proceedings, Pharmaceutical Law & Industry Report (April 3, 2015).
124
U.S. Patent No. 4,842,853, col. 1, ll. 15-20, 34-44 (issued June 27, 1989).
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– useful for products like air fresheners.125 If the inventors had wanted a
narrow patent covering only one type of scent, including one example in the
patent might have been enough. However, the inventors sought a broader
patent – covering slow release of many different “fragrant substances.”126
Thus, it was necessary to include more examples in the patent. Perhaps lacking
the time or money to conduct experiments with many different types of
fragrant substances, the inventors wrote 7 prophetic examples with instructions
for how to make these compositions.127 These included ingredients, amounts,
and mixing instructions for making scents such as “Sea Breeze,” “Lilac
perfume oil,” and “Lily of the valley.”128 Though these protocols were all
predictions, rather than tested conclusions, but they were enough for the
examiner to grant the broad patent.
Finding an alternative to carcinogenic deodorizers is a worthwhile
innovation of the type we hope to incentivize with patents. If these inventors
could only have gotten a narrow patent covering one scent, it might not have
been enough of a reward to incentivize the initial invention. Prophetic
examples allowed the inventor to get a broader patent. Without prophetic
examples, this technology may never have been made available to the public.
2. Special Situations
Prophetic examples may be useful in a variety of situations where the
inventor is not able to conduct a real experiment. In these situations, prophetic
examples create exclusivity where it would not otherwise be available,
potentially incentivizing innovation. One such situation occurs when a small
company cannot afford to conduct a large number of experiments (to get a
broader patent) before a patent is filed. Prophetic examples may help equalize
the availability of broad patents between companies with resources and those
without.129
Another such special situation where prophetic examples are needed for
filing a patent is the catch-22 situation where a funder will not provide capital
without a patent, but the experiments necessary to get the patent cannot be
done without funding. Using prophetic examples to file before the experiment
is actually conducted also helps patentees who risk losing the ability to patent
125

Id.
Id.
127
Id. at col. 3, l. 18 – col. 4, l. 53.
128
Id. at col. 3, ll. 19, 40, 65.
129
See Aisenberg, supra note 101, at 30 (explaining that prophetic examples are important
because “an individual inventor in the chemical arts is already hard put to perform or obtain
testing often required to procure a reasonable scope of patent protection.”). There is concern in
other contexts that the patent system disadvantages small companies and individual inventors.
E.g., Clark Asay, Patenting Elasticities, 91 S. CAL. L. REV. (forthcoming 2018); Polk Wagner
& David Abrams, Poisoning the Next Apple? How the America Invents Act Harms Inventors,
65 STAN. L. REV. 517, 534 (2013).
126

if they obtain data before filing a patent. This occurs because an inventor’s
own public disclosure about the invention can bar him from later filing for a
patent on the invention.130 What precisely constitutes a public disclosure is
contextual, but it may occur if samples are sent out for testing131 or
manufacturing.132 A particularly contentious issue is the question of clinical
trials, where a drug must be distributed to doctors and patients and certain
disclosures must be made. Though appropriate confidentiality agreements can
prevent clinical trials on a drug from blocking later patenting of the drug, it is a
sufficiently problematic issue that the question is frequently litigated.133
Moreover, there may be regulatory obstacles to conducting real
experiments. It is conventional in the pharmaceutical industry to file patents on
treatments that show promise in in vitro – lab based – experiments.134 It can
take years, and hundreds of millions of dollars, to obtain FDA permission for
human experiments and to conduct those experiments.135 It is risky to make
this investment without patent protection. Thus, pharmaceutical companies
generally require a patent early in a drug’s lifecycle and, crucially, before
human data can possibly be obtained.136 Though it is not strictly necessary to
include human data to obtain a patent on a drug, patents lacking human data
have occasionally been invalidated, therefore pharmaceutical companies prefer
to include human trials.137
130

35 U.S.C. § 102.
E.g., Pronova Biopharma Norge AS v. Teva Pharmaceuticals USA, Inc., 549 Fed.
Appx. 934, 939 (2013) (finding that the plaintiff’s patent was invalid because the company had
sent samples to a consultant for testing and promotional purposes before the patent application
was filed).
132
The Federal Circuit has recently clarified that a manufacturing contract to produce a
product is not a disclosure that bars later patenting assuming appropriate confidentiality
requirements are met, but this has historically been an area of concern for innovators. The
Medicines Co. v. Hospira, Inc., (Fed. Cir. July 11, 2016)
133
See, e.g., Dey, L.P., v. Sunovion Pharmaceuticals, Inc., 715 F.3d 1351, 1358 (2013)
(explaining that “courts have routinely rejected the argument that such an arrangement [clinical
trials] strips the trial of confidentiality protection or renders it accessible to the public.”). See
also Bayer Schering Pharma AG v. Barr Labs, Inc., 2008 WL 628592, at *11-12 (D.N.J. Mar.
3, 2008); Eli Lilly & Co. v. Zenith Goldline Pharm., Inc., 364 F.Supp.2d 820, 273 (S.D.Ind.
2005), In re Omeprazole Patent Litig., 490 F.Supp.2d 281, 508 (S.D.N.Y. 2007), aff’d on other
grounds, 536 F.3d 1351 (Fed. Cir. 2008); Janssen Pharmaceutical N.V. v. Eon Labs Mfg., Inc.,
374 F.Supp.2d 263, 276 (E.D.N.Y. 2004), aff’d 134 Fed.Appx. 425, 430 (Fed. Cir. 2005).
134
Rebecca S. Eisenberg, The Role of the FDA in Innovation Policy, 13 MICH.
TELECOMM. & TECH. L. REV. 345, 348 (2007).
135
Joseph A. DiMasi, Ronald W. Hansen, & Henry G. Grabowski, The Price of
Innovation: New Estimates of Drug Development Costs, 22 J. HEALTH ECON. 151, 162 (2003).
136
Eisenberg, supra note 134, at 348.
137
Note that patents are not invalidated solely for lacking human data, but rather for an
insufficient connection between the claimed utility of the invention and the evidence in the
specification. See In re ‘318 Patent Infringement Litigation, 583 F.3d 1317, 1327 (Fed. Cir.
2009); Rasmusson v. Smithkline Beecham Corp., 413 F.3d 1318, 1323-25 (Fed. Cir. 2005); In
re Brana, 51 F.3d 1560, 1566-68 (Fed. Cir. 1995) (reversing the BPAI’s rejection of the patent
and explaining that “FDA approval, however, is not a prerequisite for finding a compound
useful within the meaning of the patent laws.”).
131
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For instance, the patent applicant in Bone Care International sought a
patent on a method of treating osteoporosis using the molecule
doxercalciferol.138 The applicant had created a detailed plan for a clinical trial
of this drug, but, probably for the reasons described above, could not wait until
completion of all trials to file the patent.139 The applicant therefore filed a
patent with working examples reporting stage I and stage II clinical trials and
several prophetic examples detailing a double-blind trial and its (prophetic)
results.140
A twelve-month double-blind placebo-controlled clinical trial is conducted
with thirty-five men and women…Analysis of the clinical data shows that
[doxercalciferol] increases…intestinal calcium absorption, as determined
by direct measurement…141
Because the PTO permits prophetic examples, the applicant could use the
results of the clinical trial to support the patentability of the compound – even
before the clinical trial had been conducted.142 Without prophetic examples,
the applicant may not have felt secure enough to invest in the necessary
clinical trials, depriving the public of a valuable drug. With prophetic
examples, Bone Care filed the patent, got FDA approval, and has sold millions
of doses of the drug under the brand name Hectorol®.143
In situations of the types outlined above, it is simply not practical for an
inventor to conduct real experiments. This means that, were prophetic
examples not allowed, these inventors might not be able to get a patent.
Without prophetic examples, we might see reduced innovation from small
companies or those in the pharmaceutical space.
***
The case for prophetic examples is founded on their benefits to patentees.
The sections above describe specific ways in which prophetic examples help
patentees. From this, we can extract several testable hypotheses. Prophetic
examples should allow patents to be (1) broader; (2) filed earlier; and (3) be
particularly useful in specific situations such as for patents filed by small
138

Bone Care Intern., LLC v. Pentech Pharmaceuticals, Inc., 862 F.Supp.2d 790, 800
(N.D.Ill. 2012).
139
Id. at 798.
140
U.S. Patent No. 5,602,116, col. 11, l. 40 – col. 12, ll. 5 (issued Feb. 11, 1997).
141
Id.
142
During a later trial, defendants challenged whether the prophetic example adequately
enabled the relevant claim. The court found that it did and that the claim was valid. Bone Care,
862 F.Supp.2d at 800.
143
Genzyme Corporation, HECTOROL – doxercalciferol injection, solution,
https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021027s015lbl.pdf (Bone Care
International sold the product to Genzyme).

entities, experiments that are expensive and cannot be done without funding,
and experiments involving clinical trials.
B. Potential Costs
To be justifiable, prophetic examples must help patentees, but it is not
enough for them to merely help patentees. The underlying assumption in the
case for prophetic examples is that they help patentees in a way that is not
harmful to the patent system more broadly. This assumption has two main
components, each of which is discussed below.
1. Chilling Downstream Research
Prophetic examples might help patentees file earlier, broader patents.
However, it is far from clear that these broader, earlier filed patents are
actually socially beneficial.144 Broad, early filed patents are supported by
adherents of the “prospect” theory of patent law145 who argue that such patents
allows patentees to coordinate technological development in that area.146 This
prevents wasteful races to invent and reduces transaction costs during
downstream development.147 These are all potential benefits of prophetic
examples.
However, some scholars worry that overly broad patents reduce
competition and block downstream innovation,148 and that early-filed patents
reflect less developed inventions and therefore lead to patents that are more
vague, useless, or, if useful, are never commercialized.149 The problem with
such patents is that they might effectively prevent others from working in the
areas surrounding the patent. First, while the patent is in force, others cannot
do their own experiments in the area covered by the patent - even if the

144

See Christopher A. Cotropia, The Folly of Early Filing in Patent Law, 61 HASTINGS
L.J. 65, 67 (2009); Lemley, supra note 10 at 245; Ted Sichelman, Commercializing Patents,
62 STAN. L. REV. 341, 343 (2010).
145
Edmund W. Kitch, The Nature and Function of the Patent System, 20 J.L. & ECON.
265, 266 (1977).
146
Samuel Oddi, Un-Unified Economic Theories of Patents – The Not-Quite-Holy Grail,
71 NOTRE DAME L. REV. 267, 275 (1996).
147
Kitch, supra note 145, at 267. It also causes patents to expire earlier, a potential benefit
to society. See John Duffy, Rethinking the Prospect Theory of Patents, 71 U. CHI. L. REV. 439,
440 (2004).
148148
E.g., Peter Menell, The Challenges of Reforming Intellectual Property Protection for
Computer Software, 97 COLUM. L. REV. 2644, 2646 (1994); Arti K. Rai, Fostering Cumulative
Innovation in the Biopharmaceutical Industry, 16 BERKELEY TECH. L.J. 813, 831 (2001).
149
See, e.g. Kimberly A. Moore, Worthless Patents, 20 BERKELEY TECH. L.J. 1521, 1540
(2005) (finding that pharmaceutical and biotechnology patents were abandoned more often
than mechanical patents, and suggesting that “these industries rush to patent new compounds
and genes (and their methods of manufacture) before knowing whether those compounds have
great utility or commercial viability.”).
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prophetic examples do not work.150 Even after the patent has expired or been
abandoned, it might still chill research in that area because others cannot get a
patent on an invention disclosed in or rendered obvious by a prophetic
example.151 Patents are given only for inventions that are new and nonobvious,
therefore material that is disclosed, and everything obvious based on that
disclosed material, is no longer patentable.152 This is true even if the subject of
the disclosure was never physically created.153 We know that companies make
strategic disclosures in their patents for the express purpose of preventing
competitors from obtaining patents.154 Prophetic examples may be one form of
such disclosure.
For instance, in Ex Parte Botond Banfi, the inventors sought to patent the
use of iodide to treat microbial diseases.155 The PTO rejected the application
on the grounds that the invention was not new because it had been disclosed in
a prior patent.156 The prior patent had indeed disclosed use of iodide, but in a
prophetic example describing the treatment of asthma (which is not a microbial
disease).157 The prophetic example is:
A 45 year old female with a history of severe asthma with a morning
peak flow of less than 3 l/sec is treated with…iodide in an aerosol
formulation, 2 mg three times daily continuously. After a week of

150

One inoperative embodiment does not mean that the patent is invalid. E.g., In re
Angstadt, 537 F.2d 498, 502-503 (CCPA 1976).
151
35 U.S.C. §§ 102-103.
152
For novelty: Ex Parte Natalya B. Danilova, 2008 WL 4768088, at *4 (BPAI 2008) (“As
to the matter of Bower [an anticipating reference] being a ‘paper patent’, assuming arguendo
that this is in fact the case, the patent is nonetheless useful under 102 and 103 as prior art. Note
that a patent need not be commercially practical to be anticipatory.”). For criticisms of this
rule, see e.g., Sean B. Seymore, Reinvention, 92 NOTRE DAME L. REV. 1031, 1031 (2017).
However, in order to anticipate a later patent, the prophetic example must be enabled. For
obviousness: Ex Parte Marek Z. Kubin and Raymond G. Goodwin, 2007 WL 2070495, *2
(BPAI 2007) (finding obviousness based on a reference, which “expressly teaches through a
prophetic example how to ‘isolate the cDNA clone using mAb C1.7, screening the protein
expression in the cell transfected with the cDNA library and cloning a corresponding cDNA
into a plasmid for sequencing.’”).
153
Ex Parte Harry Fisch, 2009 WL 2760600, *6 (2009) (“Appellant also argues that the
test study designed by MacLean is a prophetic example…However, anticipation does not
require actual performance of suggestions in a disclosure, only that those suggestions be
enabling to a skilled artisan. Therefore this argument is not persuasive…”). Or, for
obviousness, even if the disclosure was not enabled. MPEP § 2121.01.
154
E.g. Scott Baker and Claudio Mezzetti, Disclosure as a Strategy in the Patent Race, 48
J. L. & ECON. 173, 174 (2005); Oren Bar-Gill and Gideon Parchomovsky, The Value of Giving
Away Secrets, 89 VA. L. REV. 1857, 1857 (2003); Rebecca Eisenberg, The Promise and Perils
of Strategic Publication to Create Prior Art: A Response to Professor Parchomovsky, 98
MICH. L. REV. 2358, 2367 (2000); Gideon Parchomovsky, Publish or Perish, 98 MICH. L. REV.
926, 927 (2000); Seymore, supra note 10, at 1058.
155
Ex Parte Botond Banfi, 2015 WL 6407275, *1 (Patent Tr. & App. Bd. 2015).
156
Id.
157
Id.

treatment the peak flow improves to 6 l/sec.158
Although the example was both prophetic and did not actually involve a
microbial disease, the court reasoned that it inherently disclosed use of iodide
to kill microbes. If someone had used the technique, it would have incidentally
resulted in the removal of microbes from the throat, even though that was not
the main purpose of the treatment.159
Though there is no evidence that this example was included for the purpose
of defensive disclosure, the example shows how use of a prophetic example
can prevent patenting in a wide area around the patent. The prior patentee
never tried using iodide to treat asthma (indeed, it is not clear that the
technique would work),160 but the patent effectively prevented others from
getting later patents on iodide to treat completely different respiratory illnesses.
Innovators are scared away from research in areas near prophetic examples
either because they believe that someone has already tried the technique or
because they worry that they will not be able to get a patent themselves.161 Any
defense of prophetic examples must balance their benefits to patentees against
this potential problem.
2. Inaccurate and Misleading
The second potential cost of prophetic examples lies in their ability to
satisfy the enablement and written description doctrines. As part of the patent
disclosure, prophetic examples need to both teach other scientists how to make
and use the invention and help inventors prove possession of the invention.162
It is only intellectually coherent to allow prophetic examples to serve these
functions if they are actually understood by scientists and if they are accurate
predictions.
To illustrate, if prophetic examples are used to teach scientists how to make
and use an invention, then they must in fact be able to do so. If prophetic
158

U.S. Patent No. 6,890,920, Example E (Issued May 10, 2005)
Banfi, 2015 WL at *3. These “inherency” rejections are made when the examiner relies
on “the inherent teaching of a prior art reference.” In re Napier, 55 F.3d 610, 613 (Fed. Cir.
1995); MPEP § 2112.
160
There were several articles on the use of potassium iodide to treat asthma published in
the 1950s and 60s, but the technique does not appear to have caught on. See, e.g., WB Casey,
On the Use of Iodide of Potassium in Asthma; Historical Document, 12 ANN. ALLERGY 728-29
(1954).
161
Though not in the context of prophetic examples, a scientist complained that “lazy
people sit in their office and say ‘we should do this’ and the next minute they write a stupid
invention disclosure and submit it…the problem is such people rarely complete these
projects…[and] someone who has the same idea will…find the patent application and assume
its been done before. I have seen personally many great ideas not being pursued because of
this.” Ouellette, supra note 10 at 564. See also Benjamin Roin, Unpatentable Drugs and the
Standards of Patentability, 87 Tex. L. Rev. 503, 545 (2009).
162
35 U.S.C. § 112.
159
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examples describe protocols that are entirely incorrect, then the patent reader
cannot rely on them for instruction on how to make the invention. Similarly, if
scientists are confused or misled by prophetic examples, then they do not
actually teach scientists anything. Further, if prophetic examples are used to
prove that the inventor had possession of the invention they must again be
accurate predictions. If the inventor’s predictions are incorrect, it is doubtful
that the inventor actually had possession of the invention described by those
same predictions. In addition, once a patent is granted, prophetic examples are
presumed to be accurate.163 The presumption is only reasonable if prophetic
examples are in fact likely to be accurate.164
At stake is not only whether patent doctrine is satisfied. The patent’s
disclosure is also supposed to promote innovation.165 The standard explanation
is that scientists get new technical information from patents and then use that
knowledge to improve the technology or make their own inventive leaps.166 If
the information in patents is confusing to these scientists or is simply
inaccurate, then it is much harder for patents to promote innovation through
disclosure.
At present, we do not know if prophetic examples reflect accurate
predictions. Some have suggested that prophetic examples are not accurate,167
but the suggestion has not been discussed in depth nor has it been tested
empirically. We similarly do not know if prophetic examples are understood
by scientists, and again, some have suggested that they are not.168 Ninety-one
percent of industry scientists read patents.169 If prophetic examples are
inaccurate and misunderstood, it presents a major challenge to the enablement
and written description requirements.
***
In order to be justifiable, prophetic examples must help patentees. But they
must also do more: prophetic examples must (1) avoid chilling downstream
research and (2) be both accurate and non-misleading.
163
Atlas Powder, 750 F.2d at 1577 (“The burden is on one challenging validity to show by
clear and convincing evidence that the prophetic examples together with other parts of the
specification are not enabling.”).
164
There are other reasons to have a presumption of validity, including administrative
simplicity and predictability for patentees. Nonetheless, the presumption is dubious if its
underlying assumption is not correct.
165
Kewanee Oil Co. v. Bicron Corp., 416 US 470, 481 (1974).
166
Id. (“[the] disclosure, it is assumed, will stimulate ideas and the eventual development
of further significant advances in the art.”).
167
E.g., Sean B. Seymore, The Teaching Function of Patents, 85 NOTRE DAME L. REV.
621, 632 (2010). Granted patents are presumed to be enabled and adequately described, and
the challenger has the burden of proving that that they are not. E.g., Impax Labs. Inc. v.
Aventis Pharm. Inc., 468 F.3d 1366, 1383 (Fed. Cir. 2006).
168
Lisa Larrimore Ouellette, Who Reads Patents?, 35 NATURE BIOTECHNOLOGY 421, 423
(2017).
169
Id. at 421 (only 78% of academic scientists read patents).

III. THE EMPIRICS OF PROPHETIC EXAMPLES: A NOVEL STUDY
Given the importance of prophetic examples to several fundamental
elements of the patent system, competing justifications and criticisms, and the
extreme dearth of scholarship on the topic, it is important to know more about
prophetic examples. This Section describes an empirical study of prophetic
examples across all electronically published U.S. patents and applications. The
study asks two primary questions. First, how prevalent are prophetic
examples? Are they sufficiently numerous to affect patents and innovation, or
are they merely an unusual – but uncommon – feature of patent law? Second,
can prophetic examples be justified?
A. Study Design
1. Populations
Unless otherwise specified, patents were issued between 1976170 and June
2017, and applications were filed between 2001171 and June 2017. I collected
data for all granted patents and applications during this period. Although the
data reported are drawn from a population, not a sample, I include tests for
statistical significance in the event that readers want to extrapolate from the
data to similar patents, for example, those from other years.172
The patents were bulk downloaded and a variety of information was
collected about each of these patents including the priority,173 filing,174 and
issue dates,175 the number of claims,176 and the number of forward and
backwards citations,177 whether the patent is a continuation178 or divisional,179
170

The USPTO full text database only covers 1976-onward.
The USPTO’s application database only covers 2001-onward.
172
I draw this strategy from John R. Allison & Lisa Larrimore Ouellette, How Courts
Adjudicate Patent Definiteness and Disclosure, 65 DUKE L.J. 609, 629 (2016). As noted by
Allison and Ouellette, because this study involves a population, coefficients may be
meaningful even if they are not statistically significant – “any observed differences in a
population are real ones.” Id.
173
The filing date of the earliest application to which the studied patent or application can
claim benefit. E.g., PowerOasis, Inc. v. T-Mobile USA, Inc., 552 F. 3d 1299, 1306 (Fed. Cir.
2008).
174
The date on which the studied application was filed. 37 C.F.R. § 1.741.
175
The date on which the studied patent issued. MPEP § 1309.
176
Each patent and application concludes with one or more claims which “particularly
point out and distinctly claim the invention.” 35 U.S.C. § 112. Some scholars suggest that
patents with more claims are broader or more important. E.g., Jean O. Lanjouw and Mark
Shankerman, Patent Quality and Research Productivity: Measuring Innovation with Multiple
Indicators, 114 THE ECONOMIC JOURNAL 441, 448 (2004).
177
Forward citations are the number of times that the studied patent has been cited by
other patents (note that this does not include citations to the application or citations by nonpatent literature). This is a rough measure of the importance of the invention. Id. Backward
citations are the number of sources that are cited by the studied patent (both those listed by the
applicant and those added by the examiner). Some scholars suggest that backward citations are
171
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IPC classifications,180 and specification length.181 This information was
obtained from patents downloaded from the USPTO’s Patent Grant Full Text
Database, hosted by Reed Tech.182 Data on patent expiration,183 maintenance
fees,184 and entity size185 was obtained from the USPTO.186
2. Identifying Prophetic Examples
Each patent was analyzed to determine if it contained an examples section,
and, if so, the section was broken down into individual examples.187 This
strategy excluded patents having no examples or integrating examples into the
text of the patent, which is a limitation of the methodology.188

correlated with patent value and perhaps breadth, though any correlation would be indirect.
E.g., Dietmar Harhoff et al., Citations, Family Size, Opposition and the Value of Patent Rights,
1596 RES. POL’Y 1, 8 (2003).
178
A continuation application has the same specification as the prior application, and uses
the same priority date, but contains different claims. U.S. Water Services, Inc. v. Novozymes
A/S, 843 F. 3d 1345, 1348 (Fed. Cir. 2016). Continuations can be used either to continue
prosecution when the examiner does not grant the original application or to file several patents
from the same base application, indicating that the applicant wants a portfolio of patents
covering the area. Mark A. Lemley & Bhaven Sampat, Examining Patent Examination, 2010
STAN. TECH. L. REV. 2, 16 (2010).
179
A divisional application, like a continuation, has the same specification and the prior
application and uses the same priority date, but contains different claims. Unlike a
continuation, a divisional carves pieces off of the original application after the original
application was found to contain more than one invention (each patent application may cover
only one invention). 37 C.F.R. § 1.142; MPEP § 201.06.
180
International Patent Classifications (IPC) are a common classification system to group
patents by the nature of the claimed technology. Guide to the International Patent
Classification
(2017),
http://www.wipo.int/export/sites/www/classifications/ipc/en/guide/guide_ipc.pdf.
181
Specification length is the number of words in the patent, excluding the abstract and the
claims.
182
Reed Tech, USPTO Data Sets; Patent Grant Red Book (2017), available at
http://patents.reedtech.com/pgrbft.php.
183
Patents expire either at the end of their 20-year term or earlier if maintenance fees are
not paid. 37 C.F.R. § 1.362.
184
Id.
185
Inventors are classified as either “large”, “small”, or “micro” entities, depending on the
nature of the organization and the number of employees. 37 C.F.R. § 1.27 (defining small
entities); 37 C.F.R. 1.29 (defining micro entities).
186
United States Patent and Trademark Office, USPTO Bulk Downloads: Patent
Maintenance Fees (2015), available at https://www.google.com/googlebooks/uspto-patentsmaintenance-fees.html#1981-present. Because micro entity status has only been available as of
2013, micro entities are counted as small entities. Additionally, the USPTO maintenance fee
records list entity size as of the date the maintenance fee was paid, which may be different
from entity size as of the date the patent was filed. This study sought to identify entity size as
of the date the patent was filed, thus, where the USPTO recorded a change from small to large
entity for purposes of payment of maintenance fees, the entity was counted as a small entity.
187
Full text of algorithm on file with author.
188
See Figure 1 for data on how many patents with examples were identified using this
strategy.

Prophetic examples were identified by exploiting a USPTO grammar
requirement: prophetic examples must be written in the present tense, while
working (non-prophetic) examples should be written in the past tense.189
Prophetic examples should be entirely in the present tense, as judges have
warned against mixing past and present tense in an example.190 Further,
examples written in the present tense are “presumed to be prophetic.”191 Where
examples consist of numbers only, and therefore have no tense, the Patent
Office assumes that the numbers are not prophetic.192
Although it is impossible to verify whether patent drafters are correctly
classifying experiments, the penalty for describing prophetic results in the past
tense is high; therefore there is reason to believe that the self-classification is
accurate. Representing a prophetic example as if it were actually conducted
may result in a finding of inequitable conduct, rendering the entire patent
unenforceable.193 There is no penalty for representing a working example as a
prophetic example, in the present tense. However, I expect that this is
uncommon for several reasons. First, patent drafting guides instruct that the
past tense be used for working examples.194 Second, courts assume that
examples written in the present tense are prophetic,195 and this has certain
disadvantages if the example is in fact working.196 Third, most patents with
prophetic examples also contain some examples written in the past tense, and it
would be surprising if a patent drafter switched to the past tense for some
working examples but left others in the present tense.
To validate the methodology, a patent agent manually reviewed a
random sample of 100 examples and classified the examples as prophetic or
non-prophetic. The patent agent identified 9 errors in the algorithm’s
MPEP § 2004 (“Paper or prophetic examples should not be described using the past
tense.”).
190
Hoffmann-La Roche, Inc. v. Promega Corp., 323 F.3d 1354, 1374 (Fed. Cir. 2003)
(Newman, J., dissenting) (characterizing the majority’s approach for concluding why prophetic
examples in the past tense constituted inequitable conduct).
191
Ex Parte Vinod Sharma and Walter H. Olson, 2010 WL 2694700, *3 (BPAI 2010). See
also Ex Parte Marlene Schwartz and Robert Richard, 2008 WL 2463016, *8 (BPAI 2008)
(“Since the examples were written in the present tense, they were presumed prophetic and do
not represent actual evidence.”).
192
E.g. Ex Parte Nobutaka Jujimoto and Masafumi Okamoto, 2013 WL 649554, *1
(PTAB 2013) (“Applicant relies on data on page 22 of the Specification. We assume that the
data is a result of actual (as opposed to prophetic) examples.”); Ex Parte Mikael Schulsky,
2009 WL 2810323, *3 (BPAI 2009) (“The specification and drawings include data…We
assume the data is not based on prophetic examples.”).
193
E.g. Novo Nordisk v Bio-Technology General, 424 F.3d 1347, 1361 (Fed. Cir. 2005).
194
E.g., SAMUEL J. SUTTON, DAVID G. CONLIN, RICHARD L. SCHWAAB, PATENT
PREPARATION & PROSECUTION PRACTICE 9.16 (1976).
195
E.g., Ex Parte Michael Prencipe and Sayed Ibrahim, 2012 WL 5387521, *7 (PTAB
2012); Ex Parte Marlene Schwarz and Robert Richard, 2008 WL 2463016, *8 (BPAI 2008)
(“Since the examples were written in the present tense, they are presumed prophetic and do not
represent actual evidence…”).
196
Most notably, the Wands factors. In re Wands, 858 F.2d 731, 737 (Fed. Cir. 1988).
189
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classification. Of these errors, the algorithm classified a working example as
prophetic 3 times and a prophetic example as working 6 times.
Once prophetic examples are identified, they can be counted. There are
multiple equally compelling ways to count prophetic examples:
• Number of prophetic examples per patent.
• Percent of total examples in the patent that are prophetic.
• Whether the patent has some prophetic examples, as compared to
patents that have no prophetic examples.
• Whether the patent has only prophetic examples, as compared to
patents that have either no prophetic examples or some prophetic
examples.
For convenience, this Article generally presents results using the first of these
measures. However, each analysis was also conducted using the other
measures, and the results were comparable. Where results are different, these
differences are noted in the text.
3. Selecting Industries
Patents are drafted differently in different industries.197 This reflects both
the varied nature of the technologies and differences in how the law is
applied.198 In particular, the bar for enablement and written description are
higher in industries such as chemistry and the life sciences as compared to the
mechanical, electrical, or computer industries.199 Thus, there is reason to
expect that examples (both prophetic and working) will be more common in
chemistry and life sciences patents. To test this, I obtained industry
classifications from NBER.200 As shown in Figure 1, examples are vastly more
common in chemical and life sciences patents.

197
See generally, Dan L. Burk & Mark A. Lemley, Policy Levers in Patent Law, 89 VA. L.
REV. 1575, (2003).
198
Id. at 1576.
199
Christopher A. Cotropia, The Folly of Early Filing, 61 HASTINGS L.J. 65, 74-75 (2009).
200
NBER classifications are used here because they are simpler and fewer in number than
IPC classifications. IPC classifications are used for the remainder of the Article because NBER
classifications are only current through 2015 and because NBER does not classify applications.

FIGURE 1: Percentage of Patents with a Separate Examples Section,
by Industry (patents issued Jan 1976-May 2017)

Note that the paucity of examples outside of the chemical and life sciences
is not because information conveyed through examples are is not present in
patents from those fields. Rather, it is attributable to drafting differences.
Mechanical, electrical and computer patents frequently contain descriptions of
embodiments – and these are frequently prophetic – but by convention drafters
in these industries do not put embodiments into a specific examples section.
Thus, the graph above should be interpreted not as indicating that examples are
infrequent in some industries, but instead as indicating that this Article’s
methodology works better for chemical and pharmaceutical patents.
Because this Article’s methodology works better for chemical and
pharmaceutical patents, the remainder of this Article studies only these
industries. All experiments and graphs below represent an analysis of only
chemical and pharmaceutical patents.
Outside of Figure 1, the population analyzed is all US chemistry and
biology patents and applications available electronically from the USPTO.
Chemistry patents are identified as those belonging to IPC classes beginning
with the code “C” (a category defined as “Chemistry; Metallurgy”). 201 Biology
patents are identified as those belonging to IPC classes beginning with the
codes A61 and A62 (categories defined as “Medical or Veterinary Science;
Hygiene” and “Life-Saving; Fire-Fighting”, respectively).202

201

World Intellectual Property Organization, International Patent Classification Scheme
http://web2.wipo.int/classifications/ipc/ipcpub?notion=scheme&version=20170101&symbol=
none&menulang=en&lang=en&viewmode=m&fipcpc=no&showdeleted=yes&indexes=no&he
adings=yes&notes=yes&direction=o2n&initial=A&cwid=none&tree=no&searchmode=smart
202
Id.
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B. The Prevalence of Prophetic Examples
Having determined that only certain industries use prophetic examples in a
format easily measured by this methodology, this Section studies a population
comprised of all chemistry and biology patents and applications. This Section
reports the prevalence of prophetic examples. If prophetic examples are rare,
perhaps we need not be concerned about their existence even if they are
theoretically problematic. If prophetic examples are common, the task of
weighing their justifications, harms, and benefits is more urgent.
As shown in Table 1, prophetic examples are indeed prevalent. Table 1
summarizes the use of examples, both working and prophetic in patents.
Approximately half of all chemistry and biology patents contain examples. Of
the patents with examples, close to a quarter contain some prophetic examples,
and about six percent contain only prophetic examples. The studied population
contains over one million prophetic examples in total.
Table 1: Prevalence of Working and Prophetic Examples

Chemistry
and biology
patents
(19762017)204
Chemistry
and biology
applications
(20012017)205

Patents in
population

Patents in
population
with
examples

Working
examples,
number
(percent)

Prophetic
examples,
number
(percent)

Patents
with no
prophetic
examples,
number203
(percent*)

Patents
with some
(but not all)
prophetic
examples,
number
(percent*)

Patents
with all
prophetic
examples,
number
(percent*)

1,160,471

559,406

5,063,847
(83%)

1,049,042
(17%)

391,839
(70%)

131,871
(24%)

35,696
(6%)

1,054,087

463,743

5,222,946
(84%)

964,321
(16%)

271,820
(59%)

177,996
(38%)

13,926
(3%)

Although prophetic examples are prevalent, their use is decreasing over
time. For patents with a priority date of 1981, when prophetic examples were
first explicitly allowed by the Patent Office, 26% of examples were prophetic
and 9.6% of patents contained only prophetic examples. By 2015, this had
dropped to 9% and 4%. Figure 3, below, shows the average number of
prophetic examples per patent in each year. This average decreases from 2.02
*

Percent of the number of patents with examples.
Utility patents only; design patents and plant patents were excluded.
205
Utility applications only; design applications and plant applications were excluded.
204

in patents with a priority date in 1981 to 1.12 in patents with a priority date in
2015.
Figure 2: Number of Prophetic Examples Per Patent Over Time (Granted
Biology and Chemistry Patents with Examples, N=559,406)

The reason for this decrease is not clear. It may be that as patents have
become more expensive to file, there is less appetite for spending attorney time
on drafting prophetic examples. It may also be that the behavior of particular
patentees has not changed, but the type of entity filing patents has changed. For
example, in the pharmaceutical industry, large companies have been filing
fewer patents and relying more on research done – and patents filed – by small
companies and universities. As discussed further in Section D(2), small
companies file fewer prophetic examples so, if they make up an increasing
share of pharmaceutical patentees, the average number of prophetic examples
per patent will decrease. As shown in Appendix 5, the use of prophetic
examples by large and small pharmaceutical patentees has stayed relatively
steady over time, but small entities file a greater percentage of all
pharmaceutical patents over time.
Overall, there are likely many reasons for the decrease in the number of
prophetic examples over time, and the dynamics surrounding the use of
prophetic examples are likely complex. Note that the percent of patents with at
least one prophetic example has not changed over time.206
206

Results not reported here. Results will be reported in an online appendix if possible.
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C. Testing the Costs and Benefits of Prophetic Examples
1. Do Prophetic Examples Help Patentees?
At its most basic, the argument for prophetic examples is that they help
patentees, and by doing so incentivize innovation and benefit society more
broadly. I begin by looking at the correlation between prophetic examples and
several general value indicators. These do not address any specific mechanisms
by which prophetic examples may affect patent value, but provides descriptive
information about the overall relationship between prophetic examples and
patent value.
I then address the specific mechanisms by which prophetic examples
should add value: breadth and early-filing. I also analyze use of prophetic
examples in the specific situations in which prophetic examples should be
especially helpful: when the inventor is a small company, when human
experiments are necessary, and when the experiments are very expensive.
a. Value
There is no perfect measure of patent value,207 but one commonly used
indicator is the maintenance rate.208 The Patent Office requires that patentees
pay maintenance fees at 3.5, 7.5, and 11.5 years after grant. These fees are
substantial enough ($1,600, $3,600, and $7,400, respectively) that many
patentees do not pay them, which results in the abandonment of the patent.209
Maintenance is a proxy for value because a patent owner that pays the
maintenance fee presumably values the patent at some amount higher than the
cost of the fee.
Figure 3 shows the correlation between number of examples – both
prophetic and working – and payment of the year 11.5 maintenance fee.210 For
each additional prophetic example in a patent, the likelihood that the
207

It is also not possible to empirically study every known facet of patent value. For
example, many patents may be valuable as signaling tools or negotiation pieces. See, e.g.,
Michael J. Burstein, Exchanging Information Without Intellectual Property, 91 TEX. L. REV.
227, 241 (2012) (describing – and questioning – the premise that intellectual property is
necessary for information exchange).
208
E.g., James Bessen, The Value of US Patents by Owner and Patent Characteristics, 37
RES. POL’Y 932, 932 (2008); Jean O. Lanjouw et al., How to Count Patents and Value
Intellectual Property, 46 J. INDUS. ECON. 405, 406 (1998).
209
United States Patent and Trademark Office, USPTO Fee Schedule (Sept. 1, 2017),
available
at,
https://www.uspto.gov/learning-and-resources/fees-and-payment/uspto-feeschedule#Patent Maintenance Fee. The fees are halved for small entities and reduced further
for micro entities.
210
Figure 3 shows the correlation between examples and the last maintenance fee,
however, results for payment of other maintenance fees are similar.

maintenance fee will be paid decreases. By contrast, the directionality of the
correlation is opposite for working examples. Figure 3 does not include
controls, however, the correlation remains when controlling for priority year,
industry, and other factors. A regression with controls can be found in
Appendix 3. Patents with more prophetic examples are less likely to pay
maintenance fees, and thus may be less valuable.

Figure 3: Relationship Between Number of Examples and Payment of
Maintenance Fees (Granted Biology and Chemistry Patents with Examples,
1981-2005, N=305,650)

A second proxy for patent value is the number of forward citations.211 If a
patent covers an important technology, others will be more likely to cite it. The
correlation between the number of prophetic examples and forward citations
per year (controlling for issue year) is reported in Appendix 3. As the number
of prophetic examples increases, the rate of forward citations decreases. This
again indicates that patents with more prophetic examples may be less
valuable.
Another common method of determining if a particular characteristic
correlates with patent value is to look at how frequently that characteristic

211

Bronwyn H. Hall et al., Market Value and Patent Citations, 36 RAND J. ECON. 16, 17
(2005). Note that forward citations are a messy and imprecise measure of patent value. C. Gay
& C. Le Bas, Uses Without Too Many Abuses of Patent Citations or the Simple Economics of
Patent Citations as a Measure of Value and Flows of Knowledge, 14 ECON. INNOVATION &
NEW TECH. 333, 335 (2005).
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appears in a specific group of patents that is known to be valuable.212 Often
this group of “valuable patents” consists of litigated patents, because litigated
patents are valuable enough to be worth challenging and defending in court.213
Appendix 3 shows the correlation between likelihood of litigation and
prophetic examples. Patents with a small number of prophetic examples show
little difference in litigation rates as compared to patents with no prophetic
examples. However, patents with many prophetic examples are considerably
less likely to be litigated.214 As with the measures above, this suggests that
patents with many prophetic examples are less valuable than patents with no
prophetic examples.
In the context of biology and chemistry patents, there is a second group of
“valuable patents”: Orange Book-listed patents. The Orange Book is a
publication maintained by the Food and Drug Administration which lists
patents covering approved drug products.215 It is expensive and time
consuming to obtain approval for a drug product, so most patents listed in the
Orange Book are extremely valuable.216
Orange Book patents are also interesting because prophetic examples are
thought to be particularly useful in pharmaceutical patents more generally.
This is because these are the patents that are most likely to have human
examples,217 the pharmaceutical sciences are fast moving,218 have a high bar
for enablement and written description,219 and are often very valuable.220 Thus,
we might particularly expect to see prophetic examples adding value in
pharmaceutical patents. However, Orange Book patents are not a uniform
group, and more study is needed to understand the uses of prophetic examples
in different types of Orange Book patents,221 as well as to understand how
212

John R. Allison, Mark A. Lemley, Kimberly A. Moore, & R. Derek Trunkey, Valuable
Patents, 92 GEO. L.J. 435 (2003).
213
Id.
214
One possibility is that the patent office has allowed invalid patents because it is not
able to fully conduct the enablement and written description analysis, but patent owners do not
believe that their patents would hold up in court and thus do not assert them. See Sean
Seymore, Patent Asymmetries, 49 U.C. DAVIS L. REV. 963, 965 (2016).
215
Food and Drug Administration, Orange Book Preface (Jan. 24, 2017), available at
https://www.fda.gov/Drugs/DevelopmentApprovalProcess/ucm079068.htm. Though widely
known as the “Orange Book,” the publication is officially titled Approved Drug Products with
Therapeutic Equivalence Evaluations.
216
C.S. Hemphill & B.N. Sampat, Evergreening, Patent Challenges, and Effective Market
Life of Pharmaceuticals, 31 J. HEALTH ECON. 327, 330 (2012).
217
TOM BRODY, CLINICAL TRIALS, 837 (2016).
218
ROBIN FELDMAN, RETHINKING PATENT LAW, 160 (2012).
219
Dan L. Burk & Mark A. Lemley, Is Patent Law Technology-Specific, 17 BERKELEY
TECH. L.J. 1155, 1183 (2002).
220
Hemphill & Sampat, supra note 216, at 328.
221
Patents may cover, for example, the active ingredient in the drug (drug substance), the
formulation or composition of the drug (drug product), or a method of using the drug. These
are often drafted at different points in the drug lifecycle, and may have very different strengths
and weaknesses. See Janet Freilich, The Paradox of Legal Equivalents and Scientific

prophetic examples relate to various types of strategic behavior that has been
documented in relation to Orange Book listing.222
Appendix 3 shows the correlation between likelihood of Orange Book
listing and prophetic examples. Unlike the value measure seen before, use of
prophetic examples does correlate with value by this measure. Orange Book
listed patents are considerably more likely to include prophetic examples as
compared to patents that are not Orange Book listed.
Orange Book listed patents are quite different from most patents – they
cover a very specific type of technology, are filed by a small set of companies,
and are often the product of extensive investment. They are also a very small
group – the FDA estimates that it listed 602 unique patents in 2014. 223 Thus,
Orange Book listed patents suggest that prophetic examples can be valuable in
that specific group, but the results are unlikely to be applicable to the broader
patent population.
Yet another proxy for value is grant rate; the likelihood that the PTO will
grant a patent. Appendix 4 shows that – unlike most of the measures seen
above – applications with more prophetic examples are somewhat more likely
to be granted than applications with fewer prophetic examples.224
b. Breadth
Prophetic examples are predicted not only to add value generally, but to do
so in several specific ways. One of these is that prophetic examples allow
patentees to obtain broader patents than they otherwise could have done. Here,
I test this claim using a proxy for patent scope: the number of words in the
shortest independent claim of the patent.225 The mechanism behind this proxy
Equivalence, 66 S.M.U. L. REV. 59, 84-87 (2013).
222
For example, merely listing a patent in the Orange Book is valuable for the patentee,
even if the validity of the patent does not hold up in court. For an overview of such strategic
behavior, see e.g., Natalie Derzko, The Impact of Recent Reforms of the Hatch-Waxman
Scheme on Orange Book Strategic Behavior and Pharmaceutical Innovation, 45 IDEA 165
(2005).
223
81 Fed. Reg. 54097 (Aug. 15, 2016). For comparison, the PTO granted 326,032 patents
in 2014. United States Patent and Trademark Office Patent Technology Monitoring Team, U.S.
Patent
Statistics
Chart
Calendar
Years
1963-2015,
available
at
https://www.uspto.gov/web/offices/ac/ido/oeip/taf/us_stat.htm.
224
This measure does not include continuations or unpublished applications. For a
discussion on the challenges of measuring allowance rate see Michael Carley, Deepak Hedge,
& Alan Marco, What is the Probability of Receiving a U.S. Patent?, 17 YALE J.L. & TECH.
203, 206 (2015).
225
Jeffrey M. Kuhn & Neil Thompson, The Ways We’ve Been Measuring Patent Scope
are Wrong: How to Measure and Draw Causal Inferences with Patent Scope, (May 2017),
available at https://ssrn.com/abstract=2977273; Alan C. Marco, Joshua D. Sarnoff, & Charles
deGrazia, Patent Claims and Patent Scope, USPTO Economic Working Paper 2016-04
(October 2016), available at https://ssrn.com/abstract-2844964.
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is that additional words in a claim add additional restrictions, thereby
narrowing the claim (for example, the set of objects in the category “sofas” is
broader than the set of objects in the category “blue sofas”). I applied this
proxy to the dataset of this Article in order to determine whether use of
prophetic examples correlated with increased breadth.
Figure 4 shows the correlation between the number of examples and the
average number of words in independent claims. As the number of prophetic
examples in a patent increases, the average number of words in the patent’s
independent claims also increases – meaning that the scope of the patent is
narrower. By contrast, the number of working examples is negatively
correlated with the scope proxy, meaning that as the number of working
examples in a patent increases, the patent is broader. Figure 4 does not include
controls, however, the correlation remains when controlling for priority year,
industry, and other factors.226
Figure 4: Correlation Between Number of Examples and Patent Breadth
(Granted Chemistry and Biology Patents with Examples, 1976-2016;
N=559,404)

226

See Appendix 3.

c. Early Filing
Prophetic examples should allow patentees to file a patent application
earlier than would be possible in the absence of prophetic examples.227 It is not
possible to measure whether a patent with prophetic examples was filed earlier
than it otherwise would have been, since the counterfactual is not observable.
However, we can observe situations in which patentees were rushing to file
applications at the patent office; situations in which they might be expected to
use prophetic examples to file quickly. One such situation occurred around the
effective date of the America Invents Act (“AIA”).
The AIA was a major overhaul of several elements of the U.S. patent
system. These changes were to some extent unfavorable to patentees, and thus
patentees rushed to file applications before the effective date of these
measures: March 16, 2013.228 Patents filed before March 16, 2013 were subject
to pre-AIA rules. Figure 5, below, shows the number of patent applications
filed each day in the month before and after March 16, 2013. The enormous
spike in applications filed in the days before the AIA came into effect is
evidence of patentees’ rush to the patent office. This rush is also confirmed by
numerous contemporary accounts.229
Figure 5: Daily Patent Applications Filed Between Feb. and June 2013
(Biology and Chemistry Applications with Examples, N=24,554)

Patentees rushing to file an application with the Patent Office would have
faced a choice: conduct time-consuming experiments that might not be
finished by March 16, 2013, or file an application with prophetic examples. If
prophetic examples are used to aid early-filing, we would expect to see an
227

Section II.A.1, supra.
Different provisions of the AIA had different effective dates.
229
Dennis Crouch, Pre-AIA Filing Number, PATENTLY-O (March 29, 2013), available at
https://patentlyo.com/patent/2013/03/pre-aia-filing-numbers.html
228
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increase in the use of prophetic examples in the days and weeks before the
effective date of the AIA, followed by a return to previous rates after the
effective date of the AIA.
Surprisingly, the number of prophetic examples used in patents filed right
before March 16, 2013 is essentially the same as the number of prophetic
examples used in patents filed after March 16, 2013 (see Figure 6). There is no
evidence that patentees were using prophetic examples to rush applications to
the Patent Office.
Figure 6: Mean Daily Prophetic Examples in Patent Applications Filed
Between Feb. and June 2013 (Biology and Chemistry Applications with
Examples, N=24,554)

***
In sum, prophetic examples are negatively correlated with most value
measures. Further, there is no evidence that use of prophetic examples leads to
broader or earlier-filed patents. Although prophetic examples do correlate with
Orange Book listings, this is unlikely to indicate a broadly applicable benefit of
such examples. Mechanisms for and implications of these findings are
discussed further in Section IV.
d. Small Entities
Proponents of prophetic examples argue that they are an equalizer between
large companies, who have the resources to conduct extensive experiments,
and small companies, who lack extensive resources.230 This Section tests how
frequently prophetic examples are used by small companies.

230

See Aisenberg, supra note 101, at 30.

The Patent Office classifies patent applications based on whether they were
filed by large entities or small entities (a category that includes individuals,
small business, nonprofits, and universities).231 Figure 7(a) shows that use of
prophetic examples is negatively correlated with small entity status; small
entities use fewer prophetic examples.
Figure 7(b) shows the total number of prophetic examples in granted
patents filed by small entities as compared to large entities. Small entities have
filed a total of 92,117 prophetic examples, while large entities have filed a total
of 611,842 prophetic examples. Thus, small entities account for only 13% of
all prophetic examples. Even if prophetic examples are justifiable on the
grounds that they are necessary for small companies, that explanation cannot
justify 87% of prophetic examples. Further, it is unlikely that prophetic
examples are necessary for most small companies, as 70% of patents filed by
small entities contain no prophetic examples. However, small entities are
somewhat more likely to use small numbers (one to three) of prophetic
examples as compared to large entities.232 This suggests that prophetic
examples may have some particular usefulness for small entities and is an area
that merits further study.
Figure 7: Use of Prophetic Examples by Small Entities (Biology and
Chemistry Granted Patents with Examples, 1981-2016, N=559,404)
7(a)

7(b)

e. Human Data
One justification for prophetic examples is that pharmaceutical companies
231

37 C.F.R. § 1.25. The Patent Office recently introduced a new category: micro entities.
Because micro entity status first became available in 2013, and therefore is not relevant to the
majority of the population studied here, I classify micro entities as small entities for purposes
of this study.
232
Appendix 3, infra.
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cannot conduct real experiments because they cannot obtain data from human
trials without FDA permission.233 I reviewed 1,000 prophetic examples
selected randomly from the population of biology and chemistry patents issued
from 1976 to 2017 to determine if the examples involved human data.
As can be seen from Table 3, below, human experiments account for only
1.9% of prophetic examples. This suggests that very few prophetic examples
are used to get around the problem of filing patents before FDA approval for
human studies. Note that although Orange Book listed patents are all related to
drugs to treat humans, only 6% of prophetic examples in those patents describe
human studies.234 Therefore use of human studies does not explain most of the
use of prophetic examples in Orange Book listed patents.
Table 3: Percent of prophetic examples that describe in vitro, cell, animal,
or human studies; N=1,000
Type of Experiment
Prophetic Examples
Human
1.9%
Animal
3.1%
Cell
3.6%
In vitro
91.4%
Even if human experiments are a justifiable use of prophetic examples, this
specific use is rare and cannot justify the vast majority of prophetic examples.
f. Expensive Experiments
Another justification for prophetic examples is in instances where
experiments would be extremely time-consuming or expensive. It is difficult to
know whether an experiment is time-consuming or expensive. As a proxy, I
reviewed the same 1,000 prophetic examples to determine if they contained
experiments on animals. Animal studies are more expensive and time
consuming than studies in cells which are in turn generally more expensive and
time consuming than studies of molecules or chemicals in test tubes (in vitro
studies), and thus are a rough alternative for data on the actual time and
expense of experiments.
Table 3 provides at least partial evidence that many prophetic examples are
based on relatively inexpensive experiments. Most prophetic examples are in
vitro experiments. While such experiments can still be expensive, they are less
expensive than in vivo experiments. Thus, expense of conducting real
experiments may not be a full explanation for use of prophetic examples.
However, I use a very rough proxy for expense here, so further study is
233

Section II.A.2, supra.
6% of a sample of 100 prophetic examples selected randomly from biology and
chemistry patents issued between 1976 and June 2017 and listed in the Orange Book as of
August 2017.
234

necessary.
2. Are Prophetic Examples Inaccurate or Misleading?
The prior section asked whether prophetic examples are beneficial because
they help patentees and concluded that there is little evidence of such a benefit.
This section asks whether prophetic examples are harmful. As set out in Part II,
such harm may arise if prophetic examples are inaccurate or mislead scientists.
a. Role of the Examiner
If patent examiners police the accuracy of prophetic examples by rejecting
examples that seem utterly implausible, we might have some confidence that
the remaining examples are likely to be accurate. Examiners have the power to
do this. They can reject a patent claim if it describes an invention that is simply
too incredible to be believable235 and can request that the applicant submit
more evidence.236 However, there is reason to doubt that examiners make such
rejections. The Patent Office emphasizes that these rejections are “rare,”
instances where such a rejection was upheld by a federal court “even rarer,”
and that requests for additional evidence “should be imposed rarely.” 237 The
Patent Office allows examiners to make the rejection only if the assertion is
“incredible in view of contemporary knowledge” and not merely where “there
may be reason to believe that the assertion is not entirely accurate.”238
To test how often patent examiners rejected patent claims because of
prophetic examples or otherwise mentioned prophetic examples, I read the
prosecution histories of 100 randomly selected patents that contained only
prophetic examples. These patents had all been rejected for lack of enablement
or utility, which is where mention of a prophetic example would be most likely
to occur. None of the prosecution histories ever mentioned prophetic examples.
This result suggests that examiners are generally accepting of prophetic
examples and do not often request corroborating data.
This result is consistent with the high grant rate for patents with prophetic
examples.239 All evidence suggests that examiners treat prophetic examples
just as they do working examples. This may reduce the overall accuracy of
prophetic examples because even those that seem incredible – such as the one
cited in the introduction of this Article – pass through prosecution without
235

MPEP § 2107.
Id. Although this rejection is allowed in the context of the utility requirement, it has the
potential to allow examiners to express skepticism of prophetic examples and request
corroborating data to bolster the prophecy.
237
Id.
238
Indeed, examiners reject applications for lack of credible utility mainly when the
claimed invention “violated a scientific principle, such as the second law of thermodynamics.”
Id.
239
Section III.D.1.a, supra.
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objection.
b. How Prophetic Examples are Cited
To directly test whether prophetic examples are misleading scientists, I
observed how prophetic examples were cited in the scientific literature. If a
document citing to a prophetic example states, either explicitly or implicitly,
that the example is hypothetical, then the citing document is correctly
interpreting the example. If the citing document refers to the prophetic
example as if the example were factual, then the citing document is incorrectly
interpreting the example.
I used a random sample of 100 patents that are cited by scientific articles.
All patents in the sample contain only prophetic examples and no working
examples. Citations do not always indicate the specific part of the patent to
which a citation refers, therefore if a patent has both prophetic and nonprophetic information, it is often impossible to know which information is
cited. Patents with only prophetic examples do not have this limitation: if a
document cites to such a patent, the document must be citing prophetic
information.
I used Google Scholar to search for non-patent references citing each
patent in the sample. I selected the first listed reference that cited the patent
substantively for a specific proposition. If a patent was not cited substantively
in Google Scholar, I excluded that patent and replaced it with another
randomly selected patent in my sample.240 I then determined whether it was
clear from the citing document that the cited information was prophetic, or
whether the citing document cited the prophetic example as if it were factual.
Strikingly, of the 100 studied patents, 99 were not cited in a manner that
made it clear that the cited information was prophetic. This strongly suggests
that prophetic examples are misleading to scientists. The article that cited a
prophetic example correctly was written by a scientist who is himself listed as
an inventor on 34 patents and applications, suggesting that he has more
experience with the patent system than most.241

240

Most patents are not cited by non-patent literature. I reviewed 912 patents to obtain the
sample of 100 cited patents used here.
241
The author is Mark R. Prausnitz, a professor at the Georgia Institute of Technology.
See Mark R. Prausnitz, Laboratory for Drug Delivery, http://drugdelivery.chbe.gatech.edu/.

Prophetic
Examples

Table 5: Miscitation of Prophetic Examples (%); N=100
Samples to illustrate categories242
“Dehydration reaction in gas phase has been carried out over solid acid catalysts…”243

Cited
Incorrectly

Cited
Correctly

“Useful synthesis methods of imidazole derivatives were known to include several
intermediates such as…1,2-diketones…”244

99%

“Hydroxyimination of aromatic ketones, followed by reduction, was used by Cannon et
al. [in a prophetic example] to synthesize conformationally restricted derivatives of
dopamine….”245
“Although the microneedle concept was proposed in the 1970s [in prophetic examples] it
was not demonstrated experimentally until the 1990s....”246

1%

c. Use of Results
As a further test of whether prophetic examples are inaccurate or whether
readers are likely to be misled, I observed whether prophetic examples
consisted just of protocols, or whether they also included experimental results.
For instance, a prophetic example might say “formulation J [a drug
compound] is be administered once daily topically to the eye of a person
suffering from glaucoma” – which is simply an experimental protocol.247
Alternatively, the prophetic example might continue with results: “[a]fter a few
hours, intraocular pressure drops more and less hyperemia [eye redness] is
observed than would be observed for formulation A.”248
If prophetic examples include results, particularly detailed results, it is an
indicator of both inaccuracy and the likelihood that readers will be misled. For
accuracy: the more results that are included in the example – and the more
detailed the results – the less likely the example is to be accurate.249 To use the
242

Samples are all excerpts from scientific journal articles.
Emphasis added. M. Suresh et al., Metal Organic Framework MIL-101(Cr) for
Dehydration Reactions, 126 J. CHEM. SCI. 527, 527 (2014).
244
Emphasis added. Heon-Gon Kim et al., Synthesis of Heteroaryl Substituted Imidazole
Derivatives, 21 BULL. KOREAN CHEM. SOC. 345, 345 (2000).
245
Emphasis added. DANIEL BLANCO ANIA, PARALLEL SYNTHESIS OF POTENTIAL DRUGS
BASED ON THE 2-ARYLETHYL AMINE MOIETY, 10 (2009).
246
Mark R. Prausnitz, Microneedles for Transdermal Drug Delivery, 56 ADVANCED DRUG
DELIVERY REVIEWS 581, 581 (2004).
247
U.S. Patent No. 8,278,353, Example 5.
248
Id. The results were included in the example, and the use of the prophetic example to
show written description was upheld by the Federal Circuit in Allergan, Inc. v. Sandoz, Inc.,
796 F. 3d 1293, 1303, 1309 (Fed. Cir. 2015).
249
Prophetic results and data should be “included in patent applications only where the
inventor has a very high level of confidence in their operability.” ROBERT D. FIER, CHEMICAL
PATENT PRACTICE 44 (1975).
243
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example above, it is surely easier to predict that formulation J will treat
glaucoma250 than to predict that it will work better than formulation A and that
the effects will occur after just a few hours.
For likelihood of misleading readers: including results in prophetic
examples– and particularly detailed numerical results – is one of the easiest
ways to confuse the reader.251 We do not usually write results for experiments
that we have not conducted. Patent readers are therefore conditioned to view
any results in experiments as the product of actual experimentation, rather than
prophesy.
Thus, whether or not a prophetic example contains results is an indication
of whether that example is both inaccurate and misleading. In order to test
whether prophetic examples contained results, I reviewed 1000 prophetic
examples selected randomly from the population of biology and chemistry
patents issued from 1976 to 2017. I classified each example in one of the three
following categories:
• No results. These examples typically described protocols or listed
ingredients without any information about the outcomes or final product.
• Some results. These examples included general information about the
results of the experiment, but did not describe specific numerical results.
Often these examples simply reported that the experiment worked and
produced the desired result. The examples sometimes include adjectives
characterizing the results in a nebulous manner.
• Detailed results. These examples included results with some detailed
description of the results. This was generally numeric results.
Table 4 shows the percent of prophetic examples in each of the three
categories and samples to illustrate the contents of each category. A majority
of prophetic examples contain at least some results, which suggests that
prophetic examples may frequently be inaccurate and misleading.

250
In fact, formulation J does treat glaucoma. The patent protects the drug Lumigan®,
which is approved by the FDA for treatment of glaucoma.
251
SUTTON, supra note 194, at § 9.17 (explaining that may be misleading if they
“conclude with a statement describing the results that were obtained…where in fact no results
have actually been obtained.”). Sutton cautions that “as a general rule, no results should be
described unless they have actually been achieved.” Id. Another guide recommended that
prophetic results and data should be “included in patent applications only where the inventor
has a very high level of confidence in their operability.” FIER, supra note 249, at 44 (1975).

Table 4: Prophetic Examples That Include Results (%); N=1,000
Prophetic
Examples
No
results

42%

Some
results

17%

Detailed
results

41%

Samples to illustrate categories252
“A solution of [several compounds] is dissolved in DMF (50 mL). The reaction mixture
is stirred under nitrogen and at room temperature for 18 h. The solvents are removed in
vacuo and the crude material is triturated in ethyl acetate, filtered and washed with ethyl
acetate. The crude product thus obtained is dissolved in 50 mL of 50% TFA/DCM and
the reaction mixture is stirred for 3 h at room temperature under nitrogen.”253
“Mice are then treated with the test article or associated vehicle by intraperitoneal
injection of 0.1 ml of the indicated solution. Mice in the first group (n=24) are treated
with vehicle…which is injected on day 0, 2, 4, 5, and 8…All the mice are sacrificed on
day 18, and lungs are collected for quantitation of tumor…In both groups of mice
created with zctyo24 or zcyto25, the average number of tumor foci present on lungs is
significantly reduced compared to mice treated with vehicle.”254
“Styrene monomer is polymerized in the presence of the rubber under dynamic
conditions for controlling the rubber particle size, after phase inversion, as the
polymerization proceeds…The composition and properties of Example 2 are shown in
Table 1 and Table 2 below. The flexural modulus of Example 2 is increased by about
10% or more (e.g., about 15% or more) compared with Example 1. The tensile modulus
of Example 2 is increased by about 10% of more (e.g., about 15% or more) compared
with Example 1. Despite having a generally high concentration of monovinyl aromatic
polymer and a generally low concentration of elastomeric polymer, Example 2 has
improved resistance to environmental stress cracking compared with Example 1…”255
IV. DISCUSSION, IMPLICATIONS, AND REFORM

In this Section, I apply the empirical findings of Section III to the costs and
benefits of prophetic examples set out in Section II. I argue that the costs of
prophetic examples are high and the benefits hard to determine, so I conclude
with suggestions for reform.
A. Do Prophetic Examples Help Patentees?
The core argument for prophetic examples is that they are valuable to
patentees, and that value to patentees translates into value to society.256
However, it is far from clear that prophetic examples actually help patentees.
First, the number of prophetic examples in a patent correlates negatively with
most proxies for patent value: maintenance, forward citations, and litigation

252

Samples are all excerpts from prophetic examples.
U.S. Patent No. 6,837,925, Example 8 (issued Jan. 4, 2005).
254
U.S. Patent No. 8,313,739, Example 31 (issued Nov. 20, 2012).
255
U.S. Patent No. 9,453,125, Example 2 (issued Sept. 27, 2016).
256
Section II.A, supra.
253
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rates.257 Similarly, although patenting guides recommend use of prophetic
examples to obtain a broader patent, use of prophetic examples is negatively
correlated with patent breadth.258 Further, there is no evidence that patentees
use prophetic examples to file early.259
Nevertheless, there are a few indications that prophetic examples add
value. First, patentees must believe that prophetic examples are useful and
increase patent value in some way; otherwise they would not use prophetic
examples. Second, prophetic examples appear more frequently in Orange Book
listed patents, although these are a small group of atypical patents, so
information drawn from these patents may not be generalizable.260 Third,
applications with more prophetic examples are more likely to be granted by the
Patent Office, suggesting that prophetic examples may add value during
prosecution.261
Overall, the results above demonstrate a surprisingly ambiguous – and
probably negative – correlation between use of prophetic examples and patent
value. However, the empirical analysis does not reveal the mechanism driving
this correlation. I suggest such a mechanism below.
1. Proposed Mechanisms
A possible mechanism to explain the results is that prophetic examples are
useful mainly in low-value patents. Under this mechanism, adding a prophetic
example to a patent would increase the value of that patent as compared to the
value of the same patent without the prophetic example. However, patentees
would only choose to add prophetic examples in situations where they were
necessary, such as instances where the patentee had no working examples or
where the patentee was in a hurry to file the application. These situations might
be those where the patent is inherently weaker.
There are many explanations for why patentees with no or little real data
might have weaker patents. A patentee might be filing a patent on a mere
guess; and that guess may turn out to be wrong, rendering the patent less
valuable. A company might file patents with prophetic examples in areas that
are not top priorities for the company, and to which the company does not want
to dedicate research dollars. Since the area was not a priority, the company
may then choose not to pursue research in that direction and abandon the
patent. A patentee may file a patent on a technology that she does not have
funding to develop. She may then never obtain the funding and abandon the
patent.
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Note that the patent’s weakness in these scenarios is not caused by the
prophetic examples themselves; rather, situations in which prophetic examples
are needed might be situations in which patents are weak.
If prophetic examples are used mainly in weaker patents, why are they
positively correlated with patent application grant rates? This may be
explained by the difference in the meaning of value at the examination stage
and value after this stage. Since examiners appear to treat prophetic examples
as equal to working examples, prophetic examples may be very valuable
indeed during examination. As theorized, they may help applicants obtain
patents when the applicant cannot conduct real experiments.
However, the real world may not view prophetic examples as kindly as
examiners. Take, for instance, a patentee who recently obtained a patent by
grace of prophetic examples. He seeks to partner with an established company
to commercialize a product. The prospective partner will ask him for evidence
that his invention works. He can produce only prophetic examples – which are
unlikely to convince investors. Alternatively, a similar patentee may, after
obtaining a patent, seek to build her product. She may discover that her
prophesies are wrong and that her product does not work. The prophecies were
enough for her to get a patent, but not enough to provide value past that stage.
2. Implications
a. Prophetic Examples May Encourage Weaker Patents
If prophetic examples add value to individual patents, but are generally
used to enable weaker patents, they may be a net loss for society. The patent
literature is replete with criticisms of weak patents.262 Weak patents are a waste
of money for both the applicant and the PTO. Weak patents increase
transaction costs for other researchers.263 Weak patents chill research in
surrounding areas.264
If prophetic examples lead to patents that are weak and abandoned at
262
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higher rates, the patent itself may not be forcing others out of the area.
However, even narrow and unenforceable patents can impede downstream
research. This is both because downstream researchers may not know that the
patent is narrow or unenforceable265 and because once an invention has been
disclosed in one patent it becomes difficult for a later inventor to obtain a
patent on a related invention.266 Awarding patents based on prophetic examples
may prevent the use of exclusivity incentives for inventors who actually
conduct the experiments.
However, any criticism on these grounds is blunted by the number of
prophetic examples in high value patents. In particular, some Orange Book
listed patents are exceedingly valuable and cover novel pharmaceutical
products that can be enormously beneficial.267 Outside of this small group,
high value patents have fewer prophetic examples than low value patents, but
high value patents nonetheless contain prophetic examples. It is very difficult
to determine whether these patents could have been obtained in the absence of
prophetic examples. This is because the enablement and written description
standards are not bright line rules and there are many different ways to enable
and adequately describe an invention. If prophetic examples encourage
wastefully weak patents (and other harms, described below), is it worth
permitting them if they add value to a smaller number of strong patents?
b. Rationales for Early Filing Do Not Fit With Prophetic Examples
There is a large literature on when patents should be filed and whether
early filing is socially beneficial. Prophetic examples have surprising
implications for this debate. Although proponents of early filing should favor
prophetic examples, I argue that the use of prophetic examples as reported in
this Article does not fit well with the benefits of early filing. The situations in
which prophetic examples are most used may also be those situations in which
early filing is the most problematic.
For instance, early disclosure is used to justify early filing. But consider
what exactly is disclosed in prophetic examples: fiction. Early disclosure of
fictional data is presumably less beneficial than early disclosure of factual data.
If prophetic examples were not permitted, patent applicants would file as early
as possible after obtaining factual data, which would provide the earliest
possible disclosure of that factual data.
265
It is difficult to know if a patent is valid, so even patents that are likely invalid can have
chilling effects. See, e.g., Mark A. Lemley, Rational Ignorance at the Patent Office, 95 Nw. U.
L. Rev. 1495, 1503 (2010).
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79 S. CAL. L. REV. 1, 30 (2006).

Moreover, prophetic examples describe the technical inner workings of the
invention, rather than a broad concept. It may be beneficial for the public to
obtain disclosure of a bright new idea earlier, in order for others to begin
working on whatever secondary innovation the idea sparks. However, the
utility of speculative disclosure of the inner workings of exactly how to make
that idea functional – synthesis methods, for example, or precise doses,
formulations, or dosage forms – is more dubious. First, it seems less likely to
spark follow-on innovation. While the idea that compound X might be an
antibiotic may lead to exciting new discoveries of related compounds that work
in similar ways, or to other uses for compound X, these types of secondary
innovation seem less likely to result from a prophetic example stating that, for
example, compound X should be administered orally in doses of 2.5 mg.
Second, the speculative disclosure of the inner workings of an invention is less
likely to be accurate than speculative disclosure of a broad concept. This is
simply because in order for the protocol to make or use the invention to be
correct, the broad concept itself also has to be correct. Moreover, a broad
concept may be wrong but may still have elements that could be useful, for
example, Jules Verne could not make a submarine, but he could inspire others
to pursue it. It seems less likely that a prophetic example describing, for
example, a protocol for manufacturing pressure-resistant screws holding the
walls of the submarine together, could be both wrong and yet so widely
inspiring.
Prospect theory is also used to justify early filing, and again, prophetic
examples do not entirely fit with this justification. An adherent of prospect
theory wants the patent to be granted early, but to someone equipped to
develop the prospect. Prophetic examples allow patentees who have not done
any experiments with a particular technology to obtain a patent on that
technology over someone who has done experiments, because the prophetic
patentee will be able to file first. However, a patentee who has done some
experimentation may be in a far better position to develop his prospect.
Further, the higher abandonment rate associated with patents with more
prophetic examples suggests that many users of prophetic examples are not
developing their prospects.
The practical reasons for early filing – that patents are needed to obtain
funding, or are needed to protect a company who must disclose the invention
in order to contract with manufacturers and the like – may be valid even for
prophetic examples. However, surely we can craft doctrine that addresses these
practical concerns in a more targeted way that creates fewer problems.
c. Why Aren’t All Examples Prophetic?
In the context of constructive reduction to practice, scholars have expressed
concerns that making patents available to inventors who have not physically
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created their invention reduces the incentive to actually build and test the
invention.268 The same argument applies to prophetic examples: if prophetic
examples are available, is there any incentive to conduct real experiments?
Apparently there is. Only 17% of examples in patents are prophetic. Given
the clear advantages of prophetic examples,269 it is surprising that more
patentees do not use them. The data on prophetic examples suggests that there
may actually be significant incentives to physically reduce an invention to
practice. This is surprising both in the context of prophetic examples and in the
larger literature on the doctrine of constructive reduction to practice, and may
temper criticisms of the latter.270
Below, I outline motivations to explain why patentees might prefer
working examples to prophetic examples; why inventors might be better off
making the invention before filing a patent.
Scientific Convention: In scientific disciplines, it is conventional to wait until
experiments have actually been run before publishing the results. Scientific
conventions often carry over to some extent into patents. 271 Scientists control
the timing of patent filing by deciding when to contact a lawyer to begin the
patenting process. It may be that, because of the strong presumption in science
that one does experiments before reporting results, scientists do not think to
begin the process of filing a patent before obtaining actual data.
Possibility of Error: While incorrect prophetic examples may not harm a patent
application, a patent application filed on a concept that turns out not to work is
a waste of time and money.272 Because filing a patent application can be
268
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expensive, inventors might prefer to conduct experiments to determine if the
invention is operative before sinking money into a patent. Patents based on
working examples should be more valuable than those based on prophetic
examples because they describe tested inventions, not guesses.273
Slight Enablement Advantage to Working Examples: The test for enablement
is whether such a skilled artisan “could make or use the invention from the
disclosures in the patent coupled with information known in the art without
undue experimentation.”274 The meaning of the phrase “undue
experimentation” has been subject to much debate, but the authoritative
method for determining whether experimentation is “undue” is application of
the Wands factors.275 Among the 8 Wands factors is “the existence of working
examples.”276 The Wands factors do not mention prophetic examples.
Although it is clear that prophetic examples can be used to enable a claim, their
omission in the Wands factors may lead patent drafters to prefer, all else being
equal, working examples.
Use as Evidence by Opponents: Prophetic examples may paint a landscape of
idealized methods for preparing a product and manners of using a product.
Being prophetic, these methods and manners are not actually completed, nor
are they always feasible. However, if the patent results in a product, and
someone is injured by the product, the injured party may try to use the
prophetic example as evidence in a products liability suit. 277 Plaintiff-oriented
products liability litigation guides recommend searching patents for proposed
safety features, some of which will be prophetic, as evidence of what the
defendant knew could be done.278 Defense-oriented litigation guides emphasize
that lawyers should attempt to exclude prophetic examples or else offer
“affirmative evidence about what was and was not done and tested.”279
contriving a ‘paper’ example often proves to be just that, unworkable except on paper.”).
273
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274
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implement those methods but has been unable to do so successfully.” Id. at 1228.
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Cost in Attorney Time: It may be cheaper to write a prophetic example than to
conduct some experiments, but it is not free. A major cost of filing a patent is
the drafting attorney’s time. Each prophetic example adds to that time. Clients
may be choosing to omit prophetic examples that are not absolutely essential.
Changes in Patentees and Patenting Practices: The Patent Office first
recognized prophetic examples in 1981. This was a period of change for patent
law, with the passage of the Bayh-Dole Act in 1980280 and the creation of the
Federal Circuit in 1982.281 The Bayh-Dole Act encouraged universities to file
patents, and “turned universities into major players” in the patent system.282
Since Bayh-Dole, the number of patents filed by universities has increased
considerably. The USPTO reports that only 594 patents were filed by U.S.
academic institutions in 1985, while 4,797 were filed in 2012. 283 Universities
are less likely to use prophetic examples – university-filed patents have a mean
of 1.5 prophetic examples compared to 1.9 for non-university patents.284 This
may be because university inventors must also publish papers in scientific
journals, which require real results.
Another possibility to explain the decrease in the number of prophetic
examples over time is the corresponding increase in claim fees during this
period. The USPTO has increased the fees for filing more than 20 claims
several times. Increased claim fees reduce the number of claims filed by patent
applicants.285 It may be that patentees cut out claims that covered more
speculative material that was not core to their invention. These claims might be
those typically enabled by prophetic examples, and thus the need for prophetic
examples may have decreased.
B. Do Prophetic Examples Confuse Scientists?
Section III asked whether prophetic examples are accurate and not
misleading or whether prophetic examples are plagued by inaccuracy and are
causes of confusion. I discuss these findings and their implications here.
280
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1. Prophetic Examples Are Often Inaccurate
Implicit in the history and doctrine of prophetic examples is the assumption
that prophetic examples are accurate.286 This Article does not directly assess
the accuracy of prophetic examples, however, it produces several results that
suggest that the assumption of accuracy is probably not correct.
First, prophetic examples in unpredictable fields such as chemistry and
biology are less likely to be correct than prophetic examples in predictable
fields such as the mechanical sciences.287 This Article shows that unpredictable
fields have a large number of prophetic examples – 536,271 examples in
chemistry patents are prophetic and 416,436 examples in biology patents are
prophetic. Prophetic examples in unpredictable fields are not inevitably
incorrect. However, their prevalence in the unpredictable sciences suggests that
we should not accept the assumption of accuracy and predictability of
inventions constructively reduced to practice without further scrutiny.
Second, the higher abandonment rate for patents with more prophetic
examples is also consistent with prophetic examples being less accurate than
working examples. Though there are many reasons why prophetic examples
might be abandoned, one possibility is that the experiment was eventually tried
and was found not to work.
Third, detailed results are common in prophetic examples. It is unlikely –
indeed, it would be surprising – if detailed examples with hypothetical
numerical data were correct in the chemical and life sciences. That is simply
not how those fields work.288 Irrespective of field, the more specific a
prediction of experimental results, the less likely it is to be correct.
Finally, prophetic examples are likely to be inaccurate because there is
little incentive to be accurate. Though patentees would prefer not to be entirely
incorrect, since that might result in a valueless patent, being merely somewhat
wrong will often not be harmful.289 Moreover, there is some advantage to
being vaguely incorrect. First, it does not give away all the cards to a
competitor.290 Second, a vague prophetic example may enable a broader claim
than a more specific prophetic example.
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The following example illustrates the advantages of vague and somewhat
incorrect prophetic examples. Allergan Plc makes the widely-marketed product
Latisse®, a prescription mascara that increases eyelash growth and
thickness.291 One of the patents covering Latisse® is directed to use of
prostaglandin F analogs to “arrest hair loss, reverse hair loss, and promote hair
growth.”292 While much of the patent’s discussion relates to scalp hair loss, the
patent includes the following prophetic example:
A mascara composition is prepared. The composition comprises:
[the example then lists 26 ingredients, including prostaglandin
F]…A human female subject applies the composition each day.
Specifically, for 6 weeks, the above composition is administered
topically to the subject to darken and thicken eyelashes.293
The prophetic example is partially right: there is a prostaglandin F analog that
darkens and thickens eyelashes, and this became the commercially available
Latisse® product. However, there are many details of the prophetic examples
that do not reflect the final product. Most notably, the specific prostaglandin F
analogs used in the prophetic example are not the same prostaglandin F
analogs used in Latisse®. In addition, the concentration of the active ingredient
is different in the prophetic example and the commercial product, as are the
inactive ingredients and the period of administration. However, the differences
between the prophetic example and Latisse® are inconsequential as a matter of
patent law. The prophetic example enabled a broad claim to “a method of
growing hair” using a broad range of thousands of different prostaglandin F
analogs. The example was somewhat incorrect, but it was nonetheless useful
for the patentee and to society, if society values eyelash thickeners.294
The likely inaccuracy of prophetic examples is troubling. Prophetic
examples are used to satisfy the enablement and written description
requirements, but both of those requirements have an underlying assumption
that prophetic examples are accurate.295 Since they are in many cases not
accurate, it is illogical to allow patentees to use false prophecies to fulfill the
disclosure requirements. This is a serious flaw in a fundamental aspect of the
patent system.
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2. Prophetic Examples Mislead Scientists
Along with an assumption of accuracy, prophetic examples also rely on the
assumption that they are not misleading.296 Above, I present direct evidence
that prophetic examples are misleading – 99% of scientific papers cite
prophetic examples as if the experiment had actually been conducted. 297 This
clearly demonstrates a deep misunderstanding of prophetic examples among
scientists. And the problem is not restricted to the citing document. The citing
document gets cited in turn by others, creating a chain where few readers
would be aware that the underlying data is fictional. Additionally, patents are
now frequently mined by databases that automatically extract information from
patents.298 This is yet another way that untried experiments can infiltrate the
general scientific literature.
The findings presented in this Article impact the already-existing literature
on problems with patent disclosure. This literature predominantly criticizes
disclosures as difficult to read, insufficiently detailed, and not updated as
research develops.299 Recent policy proposals have recommended either
improving or updating patent disclosures or encouraging the development of
ancillary information sources.300 However, some scholars criticize these
proposals, arguing that disclosure is good enough,301 should not be a priority
for the system,302 or that focus on the disclosure requirements detracts from
296
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incentives for patentees to create physical embodiments of their inventions.303
My data on prophetic examples strengthen broader criticisms of disclosure
and lend urgency to calls for reform. Prophetic examples confuse scientists and
spread misinformation. By doing so, prophetic examples function in a way that
is antithetical to the disclosure function of patents. Prophetic experiments are a
clear example of how patent disclosure is problematic.
Prophetic examples are also consistent with a second line of disclosure
scholarship. This literature focuses specifically on the criticism that
conventions in patents are so different from writing conventions outside of
patents that non-patent lawyers cannot understand patents.304 The conventions
around prophetic examples are a world away from those dictating how
scientific experiments are normally written, and this discrepancy is likely
responsible for scientists’ confusion surrounding prophetic examples. Below, I
outline some of these differences and how they create confusion.
First, as they relate to prophetic examples, the rules of scientific writing are
entirely opposite to the rules of patent writing. One scientist familiar with
prophetic examples notes that writing a prophetic example in a scientific article
would be “outright fraud”305 while another explains that a scientific paper
“should not, in fact, have any prophetic component to it whatsoever. It better
not. Unless its fraud.”306 One scientist reacted colorfully to learning about
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prophetic examples, “[w]hat I call a fake experimental procedure is actually a
prophetic example. What I call bullshit is a modus operandi.”307 The way that
experiments are written is not only different in scientific articles as compared
to patents; the practice of writing prophetic examples is actively offensive to
many scientists.
Prophetic examples not only deviate from scientific norms, they also
deviate from the norms of everyday speech. In everyday conversation, the
speaker is discouraged from making hypothetical statements unless these are
expressed as opinions, hopes, or otherwise clearly marked as statements
without evidentiary support.308 Prophetic examples do not follow these
conventions.
To the extent that prophetic examples confuse scientists, they are arguably
unconstitutional. The Constitution authorizes patents to “promote the Progress
of Science.”309 The Supreme Court has explained that “[i]nnovation,
advancement, and things which add to the sum of useful knowledge are
inherent requisites in a patent system” governed by that constitutional
command.310 There has been little discussion of the meaning of “progress”311
and courts have recently declined to find intellectual property provisions
unconstitutional.312 However, there is at least a plausible argument that if
prophetic examples mislead and hamper scientists they are regressing “the
Progress of Science.”
If it is important to have a patent system that provides information to
scientists, it is vital that scientists properly understand the information so
conveyed. To the extent that prophetic examples confuse readers, they are not
compatible with the disclosure goal of the patent system.
***
Prophetic examples are justified on the grounds that they add value to
patentees, which in turn incentivizes innovation that benefits society, that they
are useful in certain special circumstances, and that they are likely to be
accurate and not misleading. While prophetic examples likely add value to
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individual patents, they appear to be present predominantly in lower value
patents, which may have some cost to society. Further, mechanisms by which
prophetic examples were predicted to add value – increasing breadth, early
filing – are not apparent from the empirical evidence. In addition, even if
prophetic examples are necessary in special circumstances, the vast majority of
prophetic examples are not used in these special circumstances, and therefore
cannot be justified on these grounds. Finally, there is evidence that prophetic
examples are both inaccurate and misleading. In their present form, prophetic
examples are a problem.
C. Reform: From Prophecies to Hypotheses
Prophetic examples are a problem. Justifications for prophetic examples
are shaky, and their harms potentially extensive. While prophetic examples
and the consequences thereof might be helpful in some instances, and perhaps
desirable if used in moderation, the traditional justifications become less
tenable as the proportion of patents partially or completely relying on prophetic
examples grows.
Yet prophetic examples are deeply ingrained in the patent system and form
an integral part of many patents. So many patentees use prophetic examples
that banning them would be a major shock to the system and potentially
drastically change the way patents are written and the value of patents.
Moreover, to be intellectually coherent, any ban on prophetic examples would
need to be accompanied by an in-depth evaluation of the role of constructive
reduction to practice in the patent system and how scope correlates with the
disclosed invention.313
Thus, banning prophetic examples entirely might therefore be too harmful
to patentees and too drastic a change to the patent system – at least right now.
Further, there are patentees who rely on prophetic examples for justifiable
reasons – such as the inability to conduct a real experiment – and prophetic
examples should not be removed without providing another mechanism to
accommodate these patentees. In addition, there is nothing inherently wrong
with making predictions about how a technology will progress in the future –
in fact, such predictions could be valuable. I propose softer measures to
mitigate the harms of prophetic examples with a less drastic shock to the patent
system.
1. Clearly Label Prophetic Examples
To address the problems of prophetic examples without banning them,
Doctrines of constructive reduction to practice are currently criticized as “tentative and
unsystematic” (Dmitry Karshtedt, The Completeness Requirement in Patent Law, 56 B.C. L.
REV. 949, 991-92 (2015)) and the Patent Office’s guidelines “are no more helpful.” Ouellette,
supra note Error! Bookmark not defined. at 7.
313

certain aspects of prophetic examples should be reformed. First, it should be
easier for scientists and engineers reading patents to understand that, even
though prophetic examples contain experimental data, it is not real data. The
present grammatical tense shift is insufficient for this purpose. It is
unreasonable to expect non-lawyers to be aware of the meaning of the tense
shift and even for lawyers who are aware the distinction is difficult to grasp.314
The Patent Office currently requires patent applications to include certain
section headings and to format some parts of the patent in standardized
ways.315 The Patent Office should add a requirement that, for applications that
include prophetic examples, the examples should all be grouped under a
heading such as “Prophetic Examples.” However, only a heading is not
sufficient because not all patent readers will understand the meaning of
‘prophetic’. Immediately underneath the heading, the PTO should require a
disclaimer, perhaps in bold or italics, explaining the meaning of prophetic
examples. This may be a phrase such as “The examples below describe
experiments that have not actually been conducted but that the patent applicant
predicts will be functional.” The beginning and end of the prophetic examples
section should be clearly delineated. It may be desirable to mandate a separate
heading for non-prophetic examples, perhaps “Working Examples” and an
explanation there indicating that these examples have actually been conducted.
These headings and explanations would make patents more user friendly and
would prevent accidental interpretation of the data in prophetic examples are
real data.
Labeling would not only help scientists, it would also prevent translation
errors. Many companies seek patent protection in more than one country.
Generally, they will file an international patent application that will go through
preliminary examination and then be examined in more detail in individual
countries when the application enters the national stage. The international
application is usually filed in the inventor’s native language and then, when it
enters the national stage, is translated into the languages of countries where
patent protection is sought.
The translation process creates an opportunity for error. Verb tense, which
currently distinguishes between prophetic and working examples, may be
mistranslated. Some patent translating guides caution that “when translating
the examples, it is important that the translation properly reflect the nature of
the example (working or prophetic).”316 This is no simple exercise as “in some
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languages there is no easy way to distinguish between the tenses.”317
Disturbingly, most patent translation guides do not mention prophetic
examples or tenses at all, suggesting that errors may arise from ignorance.
Some firms caution, “one cannot assume that the foreign associates will
translate the application correctly.”318 Moreover, there is greater potential for
confusion in jurisdictions that do not accept prophetic examples.319
The proposal to clearly label prophetic examples is the most feasible of the
changes contemplated by this Article. It is relatively simple and easy to
implement, and the costs associated with compliance are minimal. Attorneys
are already mindful of what information in patents is prophetic, as they must
consciously switch to writing in the present tense, so simply adding a
standardized title and disclaimer should not require significant attorney or
inventor effort. Further, patent attorneys may favor the policy proposal
because heightened separation of prophetic and working examples during the
prosecution process may prevent accidental inclusion of prophetic information
in the past tense, which is inequitable conduct.
Additionally, it would be helpful to ban results in prophetic examples.
Results are probably the most misleading part of prophetic examples and the
greatest deviation from scientific norms. Not all prophetic examples include
results, but clearly many do. Removing results from prophetic examples would
prevent some of the confusion surrounding prophetic examples.
Further, banning results would have a minimal effect on patentees. Patent
applicants often need to include examples for enablement or written
description purposes, but nothing in patent doctrine requires these examples to
have results or interprets the example as more valuable to patent validity if it
has a result. There are some doctrines, such as utility, where the ultimate use
of the invention would still have to be stated in the patent, but there is no
reason that would have to be done in the context of a prophetic example. Thus,
banning results in prophetic examples would benefit the reader with little harm
to the patentee.
2. Give Patentees a Grace Period to Update Prophetic Examples
In some cases, patent applicants fully intend to conduct the experiments
recounted in prophetic examples. These applicants file prophetic examples
because they are not able to conduct the experiments before the application
needs to be filed. This can occur for many reasons such as temporary lapses in
317
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funding, needing the patent before funding can be obtained, or long approval
processes for human trials. These may be legitimate uses for prophetic
examples.
If patentees plan to conduct the described experiments, they should be
allowed to file a patent with prophetic examples as a placeholder with the
requirement that they update the patent within a period of time with the results
of the experiment. Experiments that do not work should be left in, but updated
with an explanation that they did not work. This would help combat
underreporting of negative results, a major problem in the research world.320
A key advantage of this policy suggestion is that it would retain some of
the benefits for patent applicants in situations where prophetic examples are
necessary. Take, for instance, a start-up who cannot raise enough money to
conduct an experiment without venture capital funding, but cannot obtain
venture capital funding without filing a patent. The start-up could file a patent
with a prophetic example, seek funding, and then update the example several
years later.
As present, it is not possible to update prophetic examples. Examples in
patents cannot be changed (other than for clerical errors) after the patent is
granted.321 It is also difficult to update examples during examination and
adding updated data would likely require the applicant to file a new application
based on the original application and therefore lose the original filing date.322
These rules should be loosened to allow patentees and applicants to update
prophetic examples. Even if requiring or encouraging updating is not desirable,
patentees and applicants should at least have the opportunity to update if they
so choose. Although this would be a major change for the US patent system,
other countries allow inventors to update their applications under certain
circumstances, suggesting that such a proposal might be workable.323
3. Remove Presumption of Enablement
If patentees had a grace period to update prophetic examples, examples that
were not updated at the end of the period should be presumptively nonenabled. An example is enabled if a person of ordinary skill in the art could
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make and use the invention based on the disclosed information.324 This means
that the example must both disclose a functional invention and disclose it in
sufficient detail that it could be replicated without undue experimentation. At
present, examples in granted patents are presumptively enabled,325 meaning
that a challenger alleging that the patent was invalid would have to prove that
the prophetic example was not enabled. If prophetic examples were
presumptively non-enabled, the burden would shift and the patentee would
have to prove that the prophetic example was enabled. If such a policy were
implemented, the patentee should be able to update the example at any point
and shift to presumptive enablement. However, this should be coupled with a
prior user defense to infringement lasting from the expiration of the grace
period to publication of the updated results in order to avoid “submarine
examples.”326
This would not only have an effect in litigation, it would also have an
effect on downstream research in the area. If a prior patent has disclosed an
invention, a later patent cannot claim it, because the invention is novel.327
However, earlier disclosure is only a bar to novelty if the earlier invention is
enabled. Since granted patents are presumptively enabled, it is risky to seek a
patent on an invention disclosed in a granted patent – even if the invention is
likely not enabled – because the later patentee must show non-enablement.
Thus, fewer inventors will conduct research in that area. If non-updated
prophetic examples were presumptively non-enabled, it might reduce the
chilling effect and encourage others to conduct experiments in these areas.
4. Evaluate Prophetic Examples Based on Underlying Evidence
When evaluating a patent for enablement, examiners should not simply
accept prophetic examples. Instead, examiners should review the example
with an eye towards determining if it would really work. Patent applicants
should include an explanation of why they believe the prophetic example
would work, including any calculations or reasoning necessary to understand
the prediction. A patent examiner could then give greater weight to wellreasoned prophetic examples in areas where the science is predictable, and less
weight to wild predictions. Greater explanation of the reasoning behind
prophetic examples would both help examiners and help patent readers
determine if the prediction is useful.
*
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I recognize that these policy suggestions would not completely remedy all
ills associated with prophetic examples. Prophetic examples should be studied
further – particularly in conjunction with the larger question of constructive
reduction to research more generally – in order to determine if greater reform
is necessary.
CONCLUSION
At least 17% of experiments in patents from the studied industries –
chemistry and biology – include made up data. The practice arose out of early
twentieth-century notions of fairness across industries as well as out of
administrative necessity. In an era where patent scholars, the FDA, and
scientists more broadly are grappling with an irreproducibility “crisis,”328 it is
time to re-think the justifications for prophetic examples. This Article presents
evidence that questions the traditional foundations for the practice of including
prophecy in patents. It further finds that patent readers, particularly scientists,
are enormously confused about prophetic examples and that such examples
lead to a plague of mis-citations and the infiltration of made up data into
reputable scientific publications. Prophetic examples are undoubtedly useful
for some patentees, but they also have clear harms. These competing effects,
combined with the ubiquity of made up data in chemistry and biology patents
means that patent scholars, practitioners, and policy makers must be more
aware of prophetic examples.
***
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APPENDIX 1: SUMMARY STATISTICS – CHEMISTRY & BIOLOGY GRANTED PATENTS
Patents are divided into ten groups based on the number of prophetic examples in the patent
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APPENDIX 2: SUMMARY STATISTICS – CHEMISTRY & BIOLOGY APPLICATIONS
Applications are divided into ten groups based on the number of prophetic examples in the Applications
Group
(Patents)
Number of prophetic
examples
Number of applications
Mean priority year
Mean number of nonprophetic (working)
examples
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APPENDIX 3: REGRESSIONS - CHEMISTRY & BIOLOGY GRANTED PATENTS
Correlation Between Number of Prophetic Examples and Value Measures

0 prophetic examples

Reference

(2)
Forward Citations
(poisson
regression;
incident rate
ratios)330
Reference

1 prophetic example

0.91***

1.05***

1.06

1.17

2 prophetic examples

0.85***

1.02***

1.15

1.55***

3 prophetic examples

0.83***

0.97***

0.92

1.35*

4 prophetic examples

0.81***

0.97***

1.06

1.21

5 prophetic examples

0.79***

1.02***

0.90

0.99

6-8 prophetic examples

0.80***

0.97***

0.96

1.67***

9-11 prophetic examples

0.75***

0.95***

0.48***

1.90***

12-17 prophetic examples

0.69***

0.95***

0.94

1.70**

18-754 prophetic examples

0.66***

0.92***

0.64**

1.28

Yes

Yes

Variable

(1)
Payment of First
Maintenance Fee
(logit regression;
odds ratios)329

Year since issuance offset

(3)
Litigated
(logit
regression;
odds ratios)

(4)
Orange Book
Listed (logit
regression;
odds ratios)

Reference
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Priority year
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1.01***
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1.02*

Foreign-filed

0.71***
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1.03***
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Industry effect
N=

329

71.64***
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Yes

Yes

Yes

455,094

497,653

559,406

559,406

Only patents issued before 2013 are included in the regression, because patents issued later will not have had
the opportunity to pay the maintenance fee.
330
Only patents issued before 2015 are included in the regression, because forward citation data was collected
from a PTO file last updated in 2014. This measure only includes forward citations by US patents, not by applications,
foreign patents, or non-patent literature.

Correlation Between Number of Prophetic Examples and Entity Size
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Entity size data was available only for patents issued between 1981 and 2013.

APPENDIX 4: REGRESSIONS - CHEMISTRY & BIOLOGY APPLICATIONS
Figure 4: Correlation Between Number of Prophetic Examples and Grant Rate

0 prophetic examples

(1)
Grant (logit
regression; odds
ratios)332
Reference

1 prophetic example
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2 prophetic examples
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Only patents issued before 2011 are included, since applications may take several years to be granted.

APPENDIX 5: EFFECT OF ENTITY SIZE TRENDS ON NUMBER OF PROPHETIC EXAMPLES IN PHARMACEUTICAL PATENTS
The number of prophetic examples has been decreasing over time. For pharmaceutical patents (defined using NBER’s industry
classification), this may be due to an increase in patenting by small companies. Clockwise from top left: 5(a) shows the decrease in
prophetic examples per patent over all pharmaceutical patents (N=233,823). 5(b) shows the increasing percent of pharmaceutical patents
filed by small entities (N=142,481); 5(c) shows that the use of number of prophetic examples per patent filed by small entities has stayed
relatively steady over time (N=41,681). 5(d) shows the same, but for large entities (N=110,800).

